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ACTIVATION OF 5’AMP-ACTIVATED PROTEIN KINASE KINASE IN THE
ISCHEMIC MYOCARDIUM.
Suzanne Baron, Ji Li, Raymond R. Russell III, & Lawrence H. Young.
Section of Cardiology, Department of Internal Medicine,
Yale University School of Medicine, New Haven, CT.
The 5’-AMP-activated Protein Kinase (AMPK) is a heterotrimeric serinethreonine protein kinase that becomes activated during physiological stress and acts to
conserve ATP by modulating a variety of cellular energy pathways.

The activation of

AMPK has been directly linked with phosphorylation by AMP-activated protein kinase
kinase (AMPKK) at a site deemed Threonine 172 (Thr172) on the a catalytic subunit of
the protein. Nevertheless, the role that AMPKK plays in regulating AMPK activity has
remained unclear as recent research has suggested that AMPKK may be constitutively
active.

Therefore, we isolated AMPKK in ischemic myocardial tissue induced by either

in vivo regional ischemia or by in vitro low-flow ischemia in isolated working hearts and
evaluated AMPKK activity, as measured by phosphorylation of Thr172 on synthetic
AMPK oti subunits or on recombinant heterotrimeric AMPK proteins.
levels of phosphorylated Thr

We found that

on endogenous AMPK were increased 2-fold (p < 0.03)

during in vivo ischemia and 2.6-fold (p < 0.01) during in vitro ischemia when compared
to control conditions.

Furthermore, Thr

phosphorylation of recombinant AMPK

proteins was increased after incubation with AMPKK isolated from ischemic tissue (p <
0.15 for in vivo ischemia and p < 0.04 for in vitro ischemia with recombinant AMPK cq
subunits; p < 0.04 for in vivo ischemia and p < 0.01 for in vitro ischemia with
recombinant heterotrimeric AMPK). These results demonstrate that ischemia increases
cardiac AMPKK activity, thereby suggesting that Thr172 phosphorylation and AMPK
activity is modulated by upstream kinases as opposed to phosphatase actions.
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Introduction
Energetic stress on the heart can result from different physiologic and pathologic
situations, including exercise, hypertension and coronary artery disease.

As a person

exercises, the skeletal muscle requires more oxygen and nutrients, thereby requiring the
heart to increase cardiac output, both by increasing stroke volume and by increasing heart
rate. Hypertension causes an increase in the afterload on the heart, thereby leading to an
increase in the work that the heart must do to continue meeting the metabolic needs of the
body.

Myocardial oxygen delivery is decreased in patients suffering from coronary

artery disease and the heart responds by operating in such a way so as to utilize the
limited oxygen in the most efficient way possible.
When cardiac stress continues over a long period of time, the heart responds with
anatomical and metabolic renovation. The heart responds to ischemia through a
phenomenon termed hibernation. When oxygen delivery to the heart is compromised as
occurs in coronary artery disease, the heart has been found to demonstrate decreased
contractility along with decreased energy metabolism (1). Researchers have found that
the ischemic, hibernating myocardium has a higher chance of recovery when normal
coronary blood flow is restored (2), indicating that the heart acts to protect itself by
modulating cardiac activity during ischemia.
Hypertrophy of the heart is a common response to both exercise and hypertension.
The increase in cardiac work, caused by exercise and hypertension, results in an increase
in the tension across the ventricular wall.

A formula derived from the law of Laplace

suggests that the myocardial wall tension is inversely proportional to the thickness of the
ventricular wall (3). Accordingly, several studies have found that there is an increase in

?

myocardial cell size within hours of an increased myocardial workload (4) (5).

By

increasing the size of the myocardial cell and thereby the thickness of the ventricular
wall, the heart is attempting to decrease the myocardial wall tension and thus compensate
for the increased cardiac workload induced by exercise and hypertension.

Signaling Pathways in the Heart
Receptor-mediated signaling pathways
On a molecular level, the heart responds to energetic stress through many,
different signal transduction pathways. Some of these signaling pathways, of which two
primary ones are the Pi-adrenergic pathway and the Angiotensin II pathway, are
mediated via the binding of ligands to receptors in the plasma membrane. When the body
senses physiologic stress, catecholamines are released and produce effects by binding to
adrenergic receptors, of which there are 4 classes (oci, 0C2, Pi, P2). Pi-adrenergic receptors
are the adrenergic receptors that are predominant in the heart, located specifically in the
sinoatrial node, the atrioventricular node and the ventricular tissue. When a stimulatory
ligand (catecholamines in this case), binds to the Pi-adrenergic receptor, a G protein, Gs,
is activated.

Gs subsequently activates adenylate cyclase, and increasing levels of the

second messenger, cyclic AMP (cAMP).
activation of protein kinase A (PKA).

Increased levels of cAMP result in the

PKA directly phosphorylates the L-type Ca2^

channel located on the plasma membrane, thereby increasing the entry of calcium into the
myocardial cell (6).

This increase in calcium current activates the release of calcium

from the sarcoplasmic reticulum, resulting in greater myocardial contractility (7).
Besides activating PKA, cAMP has also been implicated in directly activating ion

3

channels present in pacemaker cells (8), thereby resulting in an increase in the rate of
phase 4 depolarization in pacemaker cells and thus an increase in heart rate.
Not only can energetic stress induce the activation of (31-adrenergic receptors, but
stress can also result in the release of Angiotensin II.

Acting via Angiotension II

receptors (ATRs) present in cardiac tissue (9), Angiotensin II has been associated with
hypertrophy and remodeling of the myocardium in response to pathologic stress, such as
heart failure and myocardial infarction (10) (11) (12) (13) (14). Like the Pi-adrenergic
receptors, the ATRs are also associated with a G protein, Gq in this case.

After

stimulation of the ATR, Gq activates phospholipase C, which cleaves phosphatidyl
inositol bisphosphate (PIP2) into the second messengers inositol-1,4,5-triphosphate (IP3)
and 1,2-diacylglycerol (DAG).
(PKC) (15).

IP3 and DAG act together to activate protein kinase C

PKC has been implicated in the regulation of gene transcription via the

activation of the activator protein-1 complex (AP-1) (7), a protein that enhances the
transcription of several genes, including the genes coding for atrial natriuretic factor and
for myosin light chain (16) (17). Furthermore, PKC has been implicated in activating cRaf, which in turn activates the Mitogen-activated-protein-kinase (MAPK) cascade, a
protein kinase system that is involved in regulating cell growth (18).
Researchers also have found that some of the effects of Aargiotensin II are
independent of Gq and PKC.

Indeed, recent studies have shown that activation of the

ATR results in the stimulation of the STAT (Signal Transducers and Activators of
Transcription) pathway, another signaling pathway involved in the regulation of cellular
growth as well as with the inflammatory response (19) (20) (21).

Although the exact

mechanism by which the ATR activates the STAT pathway is still unknown, it has been
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theorized that the ATR may interact with soluble protein tyrosine kinases and/or with the
Janus Kinase Family (JAKs), both of which have been shown to directly activate the
STAT pathway (21) (22) (23).

Taken together, it appears that Angiotensin II utilizes

multiple mechanisms, including PKC and STAT activation, to exert a significant effect
on the growth of the myocardial cell.

Non-receptor-mediated signaling pathways
Unlike the [31-adrenergic and the Angiotensin II pathway, other stress-activated
signaling pathways in the heart are not dependent upon activation via a plasma membrane
receptor, but instead exert effects by other sensing mechanisms. Mechanical stretch of a
cell, as caused by volume overload, has been determined to be a potent activator of
multiple different signaling pathways, all of which are intimately involved with the
regulation of cell growth. Indeed, stretch can directly activate specific ion channels (socalled stretch-activated ion channels) (24) as well as activate the G protein, Gq (25),
which stimulates PKC and thus affects the transcription of cell growth through the
MAPK cascade as detailed above.

The G protein Ras, which activates the MAPK

cascade, as well as phospholipase C were both found to be activated following stretch of
integrin-associated cell adhesions in cardiac fibroblasts (26) (27).

Furthermore,

researchers have discovered that several humoral molecules involved in cardiac
remodelling are released following stretch, including Angiotensin II (see above
discussion), (28) and insulin-like growth factor, a molecule involved in the normal
growth of the heart (29) (30). Cytokines of the IL-6 family are also released following
stretch and act to stimulate the JAK-STAT pathway via gp!30 (31) (32). Clearly then,
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mechanical stretch serves as a powerful stimulant of several diverse signaling pathways
associated with cellular growth.
Studies have convincingly identified hypoxia as another condition, which is
capable of activating several different non-receptor mediated signaling pathways in the
attempt to maintain function. Hypoxia-inducible factor l(HIF-l) is a transcription factor
that is upregulated in situations of low oxygen pressure (33) (34).

Once HIF-1 is

activated, it increases the transcription of multiple genes, including erythropoiten (35), a
hormone that stimulates erythropoiesis, vascular endothelial growth factor (36), which is
involved in angiogenesis, the glucose transporter GLUT1 (37) and lactate dehydrogenase
(38), an enzyme involved in the anaerobic process of glycolysis.

By upregulating the

expression of all of these genes, HIF-1 acts to increase oxygen delivery to peripheral
tissues and to keep the cell well-supplied with glucose and the enzymes necessary to
produce energy in an anaerobic manner.
Hypoxia has also been shown to stimulate other transcription factors, such as
nuclear factor kB (NF-kB) and heat shock factor-1 (HSF-1) (39) (40) (41) (42). Hypoxic
stimulation causes NF-kB to increase the expression of cytokines, especially IL-8, (43)
and intracellular adhesion molecules (ICAMs) (44). Both the cytokines and ICAMs are
involved in attracting neutrophils and other inflammatory cells to a site of hypoxic injury.
Hypoxia increases levels of HSF-1, which is a molecule involved in modulating the
expression of heat shock proteins (HSPs). HSPs are a family of proteins that facilitate the
folding of newly synthesized proteins and have been implicated in protection of the
ischemic myocyte (45) (46). Thus, as the myocardial cell is exposed to the toxic stress of

6
hypoxia, the gene expression of immediate and long-term protective proteins are
upregulated through multiple signaling pathways.
Changes in whole body substrate metabolism and circulating substrate levels can
also trigger the activation of cardiac metabolic pathways through a variety of
mechanisms. A well-studied set of transcription factors that is regulated by shifts in the
level of free fatty acids is the peroxisome proliferator-activated receptor family (PPARs).
Studies have demonstrated that PPARa is involved in upregulating genes associated with
several steps of fatty acid [3-oxidation (47) (48) (49) (50).

Following even short-term

starvation, fatty acid uptake into the myocyte increases as the cell readies itself to call
upon fat stores to continue vital energy-consuming processes. Accordingly, medium and
long chain fatty acids have been identified as directly-binding ligands of PPARa (51).
Recent studies involving transgenic mice, deficient in PPARa, concluded that PPARa
activation was absolutely necessary for the increased expression of fatty acid (3-oxidation
enzymes observed during short-term starvation and thus for survival (52). Such a study
indicates the necessity of tight regulation of cardiac energy metabolism, to which the
PPAR family contributes.

Another signaling system that is exquisitely sensitive to

changes in cardiac metabolic homeostasis and responds with both acute and chronic
adjustment of energetic processes is centered around the AMP-activated protein kinase,
which is the topic of this investigation.
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The AMP-Activated Protein Kinase
The Structure of AMPK
AMPK is a heterotrimeric serine/threonine protein kinase, consisting of a catalytic
a subunit, a regulatory y subunit and the |3 subunit, responsible for connecting the a and y
subunits. Different isoforms of each of the subunits of AMPK have been identified and
specific isoforms have been associated with specific tissue distribution and varying levels
of activity. The a subunit (63 kDa) is composed of three domains. The kinase domain of
the a subunit (amino acids 1-312) is located near the N terminus and is responsible for
the catalytic activity associated with the a subunit (53).
that phosphorylation of a threonine residue (Thr

Researchers have determined

) located within this kmase domain is

necessary for AMPK activity. Indeed, site-specific mutagenesis of Thr

to an alanine

residue has been found to result in an inactive catalytic subunit (53) (54). Adjacent to the
kinase domain of the a subunit lies an amino acid sequence (termed 312-392) that has
been shown to serve as an autoregulatory sequence. Truncation of the a subunit to amino
acid 392 (1-392) results in a complete loss of catalytic activity, while further truncation to
amino acid 312 (1-312) results in a protein kinase fragment that is no longer dependent
on the allosteric activation of AMP, and thus is constitutively active (53).

Taken

together, these findings suggest that the 312-392 sequence acts as an automhibitory
domain. Lastly, the C-terminus of the a subunit (392-548) is responsible for binding the
P and y subunits, as demonstrated by a loss of (3-y binding when the C terminus of the a
subunit is removed (53).
The a subunit is present in two different isoforms (ai and

, ).

02

While the ct]

subunit seems to be more prevalent in the lung, kidney and testis (55), high levels of the

a2 subunit have been demonstrated in the heart and skeletal muscle (55) (56).
Furthermore upon activation, the ot2 subunit has been associated with greater kinase
activity in skeletal muscle (57) (58) (59) and in heart (60).
The [3 subunit (38 kDa) provides a scaffold for the catalytic a subunit and the
regulatory y subunit to assemble. The C-terminus of the P subunit contains an 84 amino
acid domain, which serves to bind the a and y subunits (61) (62).

The rest of the P

subunit is comprised of a sequence that has been shown to bind glycogen, thereby
facilitating an interaction between AMPK and glycogen stores (63). Two isoforms (Pi
and p2) have been identified for the p subunit of AMPK, with the p2 subunit being highly
expressed in skeletal and cardiac tissue and the Pi subunit showing high levels primarily
in the liver (62).
The final subunit (y) of AMPK is thought to be responsible for much of the
molecular and physiologic regulation of AMPK. The y subunit consists of four repeats of
the CBS domain, a structural protein motif that is involved in the allosteric regulation in
numerous other proteins, most notably in cystathione P-synthase (64).

Similarly, the

CBS domains of the y subunit of AMPK also seem to be involved in allosteric regulation
of the kinase, as shown by labeling studies, which have demonstrated that the AMP
analogue, 8-azido-[3~P]AMP, binds directly to the y subunit (55). Furthermore, mutations
within the CBS domains of the y subunit of AMPK result in a defective kinase that is no
longer activated by AMP (65).
Researchers have isolated three isoforms (yi, y2, y3) of the y subunit of AMPK. In
most tissues (lung, liver, heart, kidney, pancreas and skeletal muscle), yi is the most
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prevalent isoform, accounting for 80-90% of the AMPK seen in the tissues, while the
remaining 10-20% of AMPK is formed using

, with y3 making a very minor

72

contribution to AMPK activity (55) (66). In the testis and the brain,

72

and y3 presence

were found to be significantly increased, especially in the brain where the three y
isoforms were present in almost equal amounts (55). Each of the y isoforms also affected
the degree to which AMP stimulated the heterotrimeric AMPK complex. Indeed, AMPK
proteins containing the

72

subunit showed the greatest dependence on AMP, followed by

yi and then y3, which had a markedly lower dependence on AMP than either of the other
two y isoforms (55).

The Activation of AMPK
AMPK has been characterized as part of a highly sensitive protein kinase cascade.
Within this cascade, AMPK is activated via phosphorlyation by AMP-activated protein
kinase kinase (AMPKK) (67).

The high-energy phosphate group is subsequently

removed by protein phosphatase 2C (PP2C) (68), thereby returning AMPK to an
inactivated state.

This cycle of phosphorylation and dephosphorylation is commonly

seen within other protein kinase families, especially the mitogen-activated protein (MAP)
kinase family (69).

Many researchers have speculated that the reason for this cyclical

arrangement of protein kinase cascades is related to the increased sensitivity of a cascade
to activating factors (70) (71).

Modeling of the AMPK system demonstrated that the

cascade was indeed exquisitely sensitive to activating nucleotides such that a

-fold
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increase in AMP resulted in a change of AMPK activity from 10% to 90% maximal
activity (72). Thus, the arrangement of AMPK within a protein kinase cascade serves to
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increase the responsiveness of the protein to the factors in charge of regulating its
activity.
The AMPK cascade is regulated by the energy status of the cell, as determined by
levels of adenine nucleotides.

Almost all energy-requiring cellular reactions are

associated with the breakdown of ATP to ADP. Since cells require ATP to function, the
cell has developed mechanisms such that depleted stores of ATP are recognized and
replaced extremely rapidly via the reaction 2ADP
adenylate kinase.

ATP + AMP, catalyzed by

The cell’s rapid response to a depletion of ATP results in the

maintenance the ratio of ADP to ATP within a very narrow limit.

The minimally

changing ratio of ADP to ATP suggests that anabolic processes are almost exactly
balanced by catabolic processes within the cell by a system that monitors the depletion of
ATP and then subsequently adjusts catabolic and anabolic reactions as needed (73).
Since ATP can be degraded to either ADP (by ATPases) or to AMP (by ligases),
the question arises as to whether the cell responds to the AMP:ATP ratio of the
ADP:ATP ratio.

Upon examination of the reaction 2ADP <--> ATP + AMP at

equilibrium, researchers have determined that the AMP:ATP ratio varies as the square of
the ADP:ATP ratio (74). For example, if the ADP:ATP ratio were to rise by a factor of
3, the AMP:ATP ratio will increase 9-fold.

Such an example clearly demonstrates the

increased sensitivity of AMP levels in indicating the energy status of the cell. Thus, it
stands to reason that AMP levels as opposed to ADP levels are most likely to serve as the
molecule that is responsible for regulating catabolic and anabolic processes (73) (74).
Multiple studies have demonstrated the activating effects of an increased
AMP:ATP ratio on the AMPK cascade.

Indeed, AMP has been shown to not only
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increase the activity of AMPK 5-fold (75) (76), but also to increase the activity of the
upstream kinase, AMPKK (77) (78). Furthermore, the binding of AMP to AMPK affects
the ability of other proteins (i.e. AMPKK and PP2C) to interact with it.

Indeed,

inactivation of AMPK by PP2C is almost completely inhibited by the binding of AMP to
AMPK (68), while the AMP-AMPK complex (78) increased AMPKK activity.
Environments that serve to decrease the AMP:ATP ratio also affect the activity of the
AMPK cascade. The dephosphorylating activity of PP2C on AMPK was increased and
the phosphorylating activity of AMPKK was decreased in the presence of extremely high
concentrations of ATP (68) (78). Clearly then, the AMPK cascade is affected at multiple
steps by an increased AMP:ATP ratio in the surrounding environment.
Physiological regulation of AMPK occurs in situations when the cell is under
energetic stress and the AMP:ATP ratio is thereby affected.

Often, pathological

conditions, such as ischemia, are responsible for energetic stress. Indeed, AMP levels are
dramatically increased following global ischemia in rat heart, and correspondingly, both
the phosphorylation of AMPK and AMPK kinase activity were also found to be increased
(79) (80) (81).

Since ischemic conditions result in both a hypoxic environment and an

environment characterized by low extracellular glucose, researchers have studied the
separate effects of each of these physiological conditions on AMPK. Low glucose levels
in pancreatic cell lines was found to increase the AMP:ATP ratio, while consequently
increasing AMPK activity (82). Furthermore, skeletal muscle cells incubated in buffers
containing 95% N2-5% C02 were also found to increase AMPK activity 7-fold (83).
Physiological stress, such as exercise, has been shown to activate AMPK as well
as pathological stress.

Using different methodologies, several researchers have shown
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that contraction of skeletal muscle fibers result in an increase in the AMP:ATP ratio in
muscle and in an increase in AMPK activity. Rats, who were exercised on a treadmill,
showed increased AMPK activity in muscle removed from the leg (84) (85). Repeated
electrical stimulation of the sciatic nerve also resulted in a rise in AMPK activity in the
gastronemius muscle as well as in an increase in free AMP levels (86). Furthermore, in
vitro contraction of isolated muscle fibers also serves to increase the activity of AMPK
significantly (83) (85) (87). Recently, exercise has been shown to increase the AMPK
activity and AMPK phosphorylation in the heart as well as in skeletal muscle. Rats were
exercised on a treadmill at different intensities and researchers discovered that as exercise
intensity increases, AMPK activity in the heart increases proportionately (60).
AMPK has been also been found to be stimulated pharmacologically. Certainly,
many studies have utilized the drug 5-aminoimidazole-4-carboxmide-riboside (AICAR)
in the study of AMPK. AICAiR is a nucleoside that is converted into ZMP by adenosine
kinase (88).

ZMP has been shown to act as an AMP analog and thus allosterically

activate AMPK as well as enhance the activation of AMPK by AMPKK (88) (89). More
recently, two classes of drugs, metformin and the thiazolidinediones, used to treat type 2
diabetes mellitus have been found to activate AMPK.

Metformin acts to lower blood

glucose levels by increasing muscle glucose uptake (90) and by decreasing glucose
production in the liver (91).

Incubation of muscle cells with metfonmn resulted in a

significant increase in AMPK activity (92). Furthermore, activation of AMPK has been
implicated in the mechanism by which metformin acts to lower blood glucose levels (93).
The thiazolidinediones are also used to treat type 2 diabetes by increasing insulin
sensitivity in peripheral tissues through their actions on the transcription factor
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peroxisome proliferator-activated receptor y (94) (95) (96). AMPK phosphorylation and
kinase activity was found to increase with time following incubation of rosiglitazone, a
thiazolidinedione,

with

muscle

cells

(92).

Thus,

AMPK

can

be

activated

pharmacologically as well as during physiologic and pathologic stress.

The Actions of AMPK
Just as there are many activating environments for AMPK, AMPK has many
targets of action once activated.

Since the ultimate goal of AMPK is to return the

ADP:ATP ratio back to physiological equilibrium, it follows that AMPK generally acts to
turn on catabolic processes and switch off anabolic processes in multiple areas of
metabolism. Several of the first AMPK targets to be identified were in the areas of lipid
and sterol metabolism and include both hydroxymethylglutaryl-CoA (HMG-CoA)
reductase,

acetyl-CoA

carboxylase

(ACC),

malonyl-CoA

decarboxylase

hormone sensitive lipase (HSL) and glycerophosphate acyltransferase (GPAT).

(MCD),
HMG-

CoA reductase catalyzes the regulatory step that converts hydroxymethylglutarate to
mevalonic acid in the synthesis of sterols, such as cholesterol.

Researchers discovered

that activated AMPK phosphorylates a serine residue (Ser 871) on the catalytic subunit of
HMG-CoA reductase, thereby inhibiting the enzyme and decreasing sterol synthesis (88)
(97) (98).
Regulation of fatty acid synthesis and oxidation by AMPK occurs primarily
interactions with acetyl-CoA carboxylase (ACC) and malonyl-CoA decarboxylase
(MCD). ACC is responsible for catalyzing the committed step in fatty acid synthesis, in
which acetyl-CoA is converted into malonyl-CoA. When ACC is inhibited, not only is
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fatty acid synthesis decreased, but fatty acid oxidation is also increased. The rate limiting
step of fatty acid oxidation, the transport of fatty acids into the mitochondria by camitinepalmitoyl transferase I (CPT1), is inhibited by high levels of malonyl CoA (99).

By

inhibiting ACC, malonyl-CoA levels decrease, thereby lifting the inhibition on CPT1 and
allowing fatty acid oxidation to proceed.

Multiple studies have shown that activated

AMPK inhibits acetyl-CoA carboxylase in liver, heart and skeletal muscle via
phosphorylation, thereby producing decreased malonyl CoA levels (84) (88) (98) (100)
and resulting in the inhibition of fatty acid synthesis and the stimulation of fatty acid
oxidation.

Malonyl-CoA levels are also affected by MCD, which is involved in

degrading malonyl-CoA.

Researchers have determined that AMPK activates MCD in

skeletal muscle, liver and adipose tissue, thereby decreasing the amount of malonyl-CoA
in cells and further stimulating fatty acid oxidation (101) (102).

Chronic AMPK

activation has also been linked with a decrease in the gene expression of ACC and fatty
acid synthase, an enzyme responsible for catalyzing several of the reactions involved in
fatty acid synthesis (103).
AMPK is also intimately involved in the regulation of triglyceride formation and
degradation.

Glycerophosphate acyltransferase (GPAT) is involved in catalyzing the

synthesis of triacylglycerols.

AMPK was found to inhibit GPAT in muscle, liver and

skeletal muscle, resulting in the decreased formation of triglycerides (102) (104).
Hormone-sensitive lipase (HSL) is an enzyme involved in the breakdown of triglycerides
into fatty acids and glycerol in adipocytes. Cyclic AMP-dependent protein kinase (PKA)
activates HSL by phosphorylation at a serine residue (Ser-563) (105).

AMPK acts to

inhibit HSL by phosphorylating the protein at a serine site (Ser-565) that is nearly
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adjacent

to

the

phosphorylation

site

of PKA,

thereby

preventing

PKA

from

phosphorylating the activating site (Ser 563) (106). In congruence with these findings,
researches have found that when cells from adipose tissues are incubated with AICAR, an
AMPK activator, lipolysis is decreased.

This finding may seem inconsistent with the

notion that AMPK is usually involved in switching on catabolic processes, as opposed to
decreasing these processes

as

seemingly is

the

case

with

HSL

and

lipolysis.

Nevertheless, scientists have speculated that by decreasing lipolysis in adipose tissue,
AMPK is attempting to conserve ATP, an action consistent with AMPK’s general goal of
replacing depleted energy stores. Unused fatty acids are recycled back into triglycerides
and cholesterol esters in an energy-consuming process. By decreasing lipolysis, AMPK
may be working to ensure that the rate at which triglycerides are broken down does not
exceed the rate at which fatty acids are consumed, thereby reducing the amount of ATPdepleting fatty acid recycling (106).
The effects of AMPK on glucose transport into the cell have also been widely
studied.

An increase in glucose uptake into the cell is usually associated with the

translocation of GLUT4 transporters to the sarcolemma, so as to facilitate the movement
of glucose across the plasma membrane.

Insulin is commonly associated with

stimulating the movement of GLUT4 transporters to the sarcolemma and exerts this
effect via the activation of phosphatidylinositol 3-kinase (107) (108). Ischemia, hypoxia
and contraction of skeletal muscle have all been associated with the translocation of
GLUT4 transporters via a mechanism that is

independent of insulin-associated

phosphatidylinositol 3-kinase activation (108) (109) (110).

Initial studies utilizing

AICAR found that glucose uptake into skeletal and cardiac muscle increased 2-fold in
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association with an increase in AMPK activity (111) (112) (113).

Using a transgenic

mouse that expressed a dominant-negative kinase-dead AMPK, researchers found that
hypoxia was unable to stimulate glucose uptake or increase GLUT4 translocation in
either in the heart (113) or in skeletal muscle (114). Furthermore, chronic activation of
AMPK by long-term AICAR administration has been shown to result in an increase in
GLUT4 gene expression (115).

Taken together, these findings strongly suggest that

AMPK stimulates glucose transport via increased expression and translocation of GLUT4
transporters by a mechanism that is not related to the insulin-linked phosphatidylinositol
3-kinase pathway.
Once glucose has been taken into the cell, AMPK is able to exert both acute and
chronic control over the storage, breakdown and synthesis of glucose. Excess glucose is
often stored as glycogen, an energy-requiring process that is mediated by the enzyme
glycogen synthase. Glycogen synthase is de-activated by phosphorylation at a site (Ser10) by casein kinase-1 (116).

AMPK has been shown to phosphorylate glycogen

synthase at a serine residue (Ser-7) (117), which serves to promotes the phosphorylation
of Ser-10 by Casein kinase-1 and thereby results in the inactivation of glycogen synthase
(116).

Glucose is broken down through the process of glycolysis, during which 2 net

molecules of ATP are made.

A potent regulator of glycolysis is fructose 2,6-

bisphosphate, a molecule that stimulates 6-phosphofructo-l -kinase, which is the enzyme
that mediates the rate-limiting step of glycolysis.

Fructose 2,6-bisphosphate is made

using the enzyme 6-phosphofructo-2-kinase (PFK-2).

AMPK has been shown to

phosphorylate heart PFK-2 at Serine-466, thereby leading to the stimulation of fructose
2,6-bisphosphate production and thus, the stimulation of glycolysis (118) (119). Over the
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Ions term, researchers have determined that chronic stimulation of AMPK results in the
change in gene expression of several gluconeogenic enzymes. AMPK leads to decreased
expression of glucose-6-phosphatase (120) (121), pyruvate kinase (122) (123), and
phosphoenolpyruvate carboxykinase (120), all enzymes involved in the key steps of
gluconeogenesis.

All in all, the effects of AMPK on glucose metabolism serve to

increase the energy stores available to the cell by stimulating catabolic processes and
inhibiting anabolic processes.
In addition to carbohydrate and lipid metabolism, AMPK has been implicated in
regulating protein metabolism through effects on p70 ribosomal protein S6 kinase
(p70S6K) and eukaryotic elongation factor 2 kinase (eEF2K). Once activated, p70S6K is
involved in the synthesis of proteins in the liver (124). Several researchers have found
that activated AMPK is associated with the inhibition of p70S6K, although the specific
mechanism of this inhibition remains elusive (125) (126) (127). Eukaryotic elongation
factor 2 (eEF2) is another enzyme involved in protein synthesis in the liver.

Upon

hypoxic stimulation, eEF2 becomes phosphorylated, which serves to inhibit the enzyme
and thus inhibit protein synthesis. Upon further study, it was determined that AMPK was
responsible for activating the upstream protein, eEF2 kinase, thereby promoting the
inhibitory phosphorylation of eEF2 (128). Thus AMPK serves to inhibit hepatic protein
synthesis by at least two different mechanisms.
Recently, researchers have discovered that AMPK interacts directly with
transcription factors in order to regulate gene expression.

Hepatocyte nuclear factor

(HNF) 4a is associated with regulating the expression of genes involved in glucose and
triglyceride metabolism, including pyruvate kinase, Apoprotein B and Apoprotein C III
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(129).

HNF4a has been identified as a substrate for AMPK, which has been shown to

phosphorylate HNF4a on a serine residue both in vitro and in cell lines.

Researchers

have speculated that the phosphorylation of HNF4a results in the degradation of the
transcription factor (as evidenced by the disappearance of the protein) and the resulting
reduction of gene transcription (130) (131).

Carbohydrate-response-element-binding

protein (ChREBP) is another hepatic transcription factor that is involved in regulating
genes encoding metabolic enzymes, including pyruvate kinase, fatty acid synthase and
acetyl-CoA carboxylase.

AMPK has been shown to phosphorylate ChREBP, thereby

inhibiting ChREBP from binding to DNA (132). Inhibition of ChREBP could serve as
another way that AMPK is able to regulate anabolic processes, specifically by interfering
with the expression of gluconeogenic proteins. The transcription cofactor, p300, has also
been identified as a substrate for AMPK (133).

Researchers have found that p300 is

involved in regulating the transcriptional activity of peroxisome-proliferator-activatedreceptors (PPARs), which are transcription factors involved in the differentiation of
adipose tissue (134) (135).

PPAR-y activity has been found to be inhibited when

activated AMPK is present, and recent studies suggest that this effect may stem from the
decreased activity of p300, due to phosphorylation by AMPK (133). Although the exact
mechanisms of the effect of AMPK on gene transcription still need to be further studied
and elucidated, it seems clear that AMPK exerts an effect on gene expression by
interacting with nuclear transcription factors.
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The AMP-activated Protein Kinase Kinase
As mentioned above, the primary molecular activator of AMPK is the upstream
kinase, AMP-activated protein kinase kinase (AMPKK).

Indeed, AMPKK has been

shown to produce a 50-fold increase in AMPK activity (88) through phosphorylation.
Early studies identified the primary site phosphorylated by AMPKK as Thr1'2 on the
catalytic subunit (67), a site that has been deemed necessary for AMPK activity as
demonstrated by the lack of AMPK activity in Thr " deficient proteins (53) (54).
Clearly then, AMPKK is an important player in the AMPK cascade.
In order to further understand the regulation and activity of AMPKK, researchers
have made attempts to elucidate the structure of the kinase. AMPKK purification from
rat liver demonstrated a molecule quite similar in structure to AMPK (67).

Indeed,

AMPKK possesses a catalytic subunit of weight 58 kDa, quite similar to the a subunit of
AMPK, which weighs 63 kDa. Overall molecular mass of the kinases were also similar
with AMPKK measuring in at 195 kDa as compared to the 190 kDa weight of AMPK.
Seeing as the structure of the two kinases is quite similar, studies have
investigated the likely possibility that similar molecular and physiologic environments
might activate AMPK and AMPKK.

Since AMPK was found to be significantly

activated by AMP and inhibited by high concentrations of ATP (75) (76), researchers
have examined the effects of AMP and ATP on AMPKK activity.

Indeed, an elegant

study was performed in which it was found that the addition of AMP resulted in a 1.5
fold increase in the phosphorylation of the catalytic subunit of AMPK after incubation
with AMPKK purified from rat liver (78). Similarly, other researchers found that AMP
addition resulted in increased AMPK activity after AMPK was incubated with purified
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rat liver AMPKK (77).

Furthermore, studies found that high concentrations of ATP

could completely inhibit the activation of AMPK by AMPKK (67). Such findings lend
credence to the notion that the kinases are similarly regulated.
Despite similar stimulation by adenosine molecules, recent work has found that
AMPKK may not be subject to the same physiologic regulation as AMPK. Since AMPK
is activated by hypoglycemia, hypoxia and AICAR, it was expected that AMPKK would
show increased activity under these conditions as well. Experiments using a bacterially
expressed recombinant .AMPK cti subunit demonstrated no change in AMPKK activity in
insulinoma cells after AICAR stimulation or exposure to a hypoglycemic environment
(136).

This finding has led scientists to conclude that AMPKK may be constituitively

active. Such results are puzzling in light of the apparent similarities between AMPKK
and AMPK both in structure and in response to AMP.
In order to fully understand the AMPK cascade, it is necessary to elucidate the
role that AMPKK plays in the regulation of AMPK activity. Clearly, some studies have
suggested that AMPKK may not be an important player in modulating the actions of
AMPK, and that instead, AMPK activation may be modified by proteins other than
AMPKK (136).

Further research is needed to understand the regulation of AMPKK

activity, so as to better understand the effects of AMPKK on AMPK activity and the
entire AMPK cascade.
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Specific Aims of Study

This research seeks to further clarify the physiologic regulation of AMPKK and
the role of AMPKK in the AMPK cascade. The first aim was to develop methods that
could enrich AMPKK and could be used to measure AMPKK activity. The second aim
was to assess the suitability of different substrates as tools for investigating AMPKK as
well as to assess the kinetics of the AMPKK reaction in order to optimize the assay. The
third aim was to utilize these newly developed methods to address the specific
physiological effects of in vitro global or in vivo regional ischemia on AMPKK activity
in myocardial tissue.
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Methods
Male Sprague-Dawley rats (250-350g) were housed in an animal facility and
given standard chow and water before experiments. All procedures were approved by the
Yale University Animal Care and Use Committee.

In Vitro Ischemia Protocol

An in vitro model of global ischemia was used to assess the effects of ischemia on
AMPKK activity. The in vitro ischemic model is a simple model in which the degree of
ischemia is able to be controlled and other potentially confounding variables, such as
hormones and neurosympathetic activation, which may have some effect on AMPK and
AMPKK activation, are able to be excluded.
Rats were anesthetized using an intraperitoneal injection of pentobarbital sodium
(60 mg/kg) and were heparinized with 300 units intraperitoneally. Hearts were excised
and placed in Krebs-Henseleit bicarbonate buffer at 4° C. The aorta was then cannulated
and the heart perfused anterogradely with Krebs-Henseleit buffer (2.5 mM Ca2+)
containing glucose (5 mM) in order to wash out any remaining blood. Subsequently, a
cannula was inserted into the pulmonary vein and the hearts were perfused in the working
heart mode (138) at 37° C with Krebs-Henseleit bicarbonate buffer containing 1% BSA
(fraction V, fatty acid free), oleate (0.4 mM), glucose (5 mM), calcium (2.5mM) and
bubbled with 95% O2 /5% CCb. Control hearts were subjected to 40 minutes of perfusion
with a preload of 15 cm H2O and an afterload of 100 cm H2O. Ischemia heart perfusion
protocol went as follows : during the first 20 minutes, hearts were perfused with a preload
of 15 cm H2O and an afterload of 100 cm HiO; during minutes 20-40, hearts were
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perfused with a preload of 15 cm fLO and an afterload of 30 cm H2O to produce a flow
that was 15% of control flow.
stored at -80° C.

After 40 minutes, the hearts were freeze-clamped and

The heart perfusion procedures were performed by Monica Palmieri

under the supervision of Raymond R. Russell III M.D. to provide myocardial tissue for
these experiments.

In Vivo Ischemia Protocol

An in vivo model of regional ischemia was also utilized during these experiments
in order to further apply these findings to syndromes seen in clinical practice.

Since

coronary artery disease is a phenomenon of regional ischemia caused by coronary artery
occlusion, it was appropriate to investigate the effects of regional ischemia produced in
vivo. Furthermore, the in vivo model includes other factors which may have an effect on

AMPK and AMPKK activity, such as varying intracardiac pressures and circulating
neurohormonal influences, thereby making the in vivo ischemic model an appropriate and
useful tool for investigation.
Rats were anesthestized using an intravenous injection of pentobarbital sodium
(60 mg/kg IP).

The rats were subsequently intubated and ventilated at 80 breaths/min

and a tidal volume of 2.5 cc with 100% oxygen.

A left lateral thoracotomy was

performed and the proximal left anterior descending artery was ligated with a 6.0 silk
suture (137). After 10 minutes, the heart was excised and freeze-clamped with aluminum
tongs, which were cooled in liquid nitrogen.

Control rats underwent the same

procedures, excepting that the left anterior descending artery was not occluded.

The
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hearts were stored at -80° C. The surgical procedure was performed by Xiaoyue Hu M.D
under the supervision of Dr. Lawrence H. Young to provide cardiac tissue for this study.

Tissue Homogenization
All procedures occurred at 4° C. Heart tissue was homogenized for 60 seconds in
homogenization buffer (125mM Tris, ImM EDTA, ImM EGTA, 250mM Mannitol,
50mM NaF, 5mM NaPPi, ImM DTT, ImM Benzamedme, 0.004% Trypsin Inhibitor,
3mM NaN3, pH 7.5). The homogenate was then centrifuged at 10,900 RPM (14,400g) on
a SS34 Rotor for 30 minutes. The pellet was discarded and the supernatant was saved.
25% Polyethylene Glycol (PEG) was added to each supernatant volume to a final
concentration of 2.5% PEG.

The samples were then agitated for 10 minutes and

subsequently centrifuged at 9,200 RPM (10,000g) for 10 minutes. Again, the pellet was
discarded and the supernatant was placed into a separate set of test tubes. 25% PEG was
added to each sample to a final concentration of 6% PEG. The samples were agitated for
10 minutes and then centrifuged at 9,200 RPM (10,000g) for 10 minutes. The pellet (2.56% PEG precipitate) was resuspended in homogenization buffer. The supernatant was
collected and placed into another set of test tubes.

Again, 25% Polyethylene Glycol

(PEG) was added to each sample to a final concentration of 10% PEG. The samples were
shaken for 10 minutes and centrifuged at 9,200 RPM (10,000g) for 20 minutes.

The

pellet (6-10% PEG precipitate) was resuspended in homogenization buffer and the
supernatant was collected (>10% supernatant).
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Protein Concentration Assay
Preparation of reagents: BioRad reagent was diluted 1:4 in distilled water.

Bovine serum albumin (BSA) was prepared at a concentration of 1 mg/lml and then
diluted 1:10 in distilled water. Sample protein was diluted 1:20 in distilled water.
Determination of protein concentration: 8007. of diluted BioRad reagent was

added to each test tube. For the BSA standards: 07. of diluted BSA was added for the
zero standard, 257. of diluted BSA was added for the 2.5pg standard, 507. of diluted BSA
was added for the 5.0 pg standard and 757. of diluted BSA was added for the 7.5pg
standard.

20X of diluted protein extract was added to each sample test tube.

Distilled

water was then added so as to bring the total volume in each test tube to lml.
conditions were run in duplicate.

All

Standards and samples were then transferred to

cuvettes and placed in a spectrophotometer with wavelength set at 5957. in the
absorbance mode. The zero standard was set as reference and the samples and standards
were subsequently read. The BSA standard curve was determined using Microsoft Excel,
and sample protein concentrations were ascertained based on the standard curve using
linear regression.

Recombinant AMPK Phosphorylation by cellular AMPKK
10 pg of PEG precipitated protein (6-10% fraction) was incubated with 10 pmol
of a recombinant AMPK cp subunit, which consisted of a/'312 with an N-terminal
maltose binding protein

(gift from Dr. Lee Witters) (136) or 5 pmol of recombinant

heterotrimeric (cp-Pi-yi) AMPK (gift from Dr. Diebert Neumann) (139) (140) in 25 pi of
incubation buffer (20mM Tris, 5mM MgCD, 0.2mM ATP, 0.5mM DTT, 0.1% Tween,
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1 mg/ml BSA, pH 7.5) for 10 minutes at 30° C.

The reaction was stopped by a 2-fold

dilution with Laemelli Sample Buffer (20% glycerol, 2% SDS, lOmM Tris, 1.2%
Mercaptoethanol, 5% Bromethylene Blue, pH 6.8). Samples were boiled for 10 minutes
prior to gel electrophoresis on an 8% gel.

Gel Electrophoresis and Immunoblotting
The running gels were made by combining 8% bis-Acrylamide, 0.375M Tris,
0.1% SDS, 0.045% APS and 0.004% TEMED, adjusted to a pH of 8.8. After the running
gel had set, the stacking gel (4% bis-Acrylamide, 0.125M Tris, 0.001% SDS, 0.001%
APS, 0.001% Temed, pH 6.8) was added.

40 pg of PEG-precipitated protein (2.5-6%

fraction) was combined with Laemelli Sample buffer and boiled for 10 minutes. 20k of
sample was loaded into each lane and then subjected to electrophoresis (200V) for 75
minutes in electrode buffer (19.3mM Tris, 18.6mM Glycine, 5mM SDS). The proteins
were subsequently transferred to methanol-soaked PDVF membranes in transfer buffer
(19.2mM Tris, 192.2mM glycine, 0.2% methanol) at 200 mAmps for 90 minutes.
Membranes were then blocked overnight with specific buffers to prevent non-specific
binding.

Membranes to be blotted for pThr172 AMPK were blocked with TBS-T milk

buffer (15mM Tris, 137mM NaCl, 5% nonfat dry milk, 0.1% Tween-20, pH 7.6).
Membranes to be blotted for total AMPK were blocked with 5% Tris milk buffer (lOrnM
Tris, 500mM NaCl, 5% nonfat dry milk, 1% Tween-20, pH 7.4).
pThr17~ Immunoblotting: The membrane was incubated with the primary antibody,

anti-pThr172 AMPK (Cell Signaling, Beverly, MA), at 1:5,000 dilution in 10ml of
primary antibody dilution buffer (15mM Tris, 137mM NaCl, 5% BSA, 0.1% Tween-20,
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pH 7.6) for 1 hour. Membranes were subsequently washed 3 times for 10 minutes each
with wash buffer (15mM Tris, 0.137M NaCl, 0.1% Tween-20, ph 7.6).

A 60-minute

incubation with the secondary antibody, HRP-conjugated goat-antirabbit IgG (Zymed,
San Francisco, CA) followed. Membranes were then washed 6 times for 15 minutes each
with wash buffer. 10ml of ECL (company name) was incubated with the membranes for
1 minute.

After membranes were blotted dry, they were placed in a plastic sheet

protector and exposed to autoradiographic film.
Total AMPK Immunoblotting: The membrane was incubated with the primary

antibody, anti-pan-a AMPK (gift from Dr. M. Bimbaum), at 1:20,000 dilution in 10ml of
5% tris milk buffer for 1 hour.

Membranes were subsequently washed 3 times for 10

minutes each with 5% tris milk buffer.

A 60-minute incubation with the secondary

antibody, HRP-conj ugated goat-antirabbit IgG (Zymed, San Francisco, CA) followed.
Membranes were then washed a total of 6 times - 2 times for 15 minutes each with 5%
tris milk buffer, 2 times for 15 minutes each with PBS and 2 times for 15 minutes each
with distilled water. Membranes were visualized as described above.

AMPK Assay
10p.g of heart homogenates (2.5-6% PEG fractions) or 0.16 pmol of recombinant
heterotrimeric AMPK were added to 25Z AMPK kinase assay buffer (0.8mM DTT,
0.2mM AMP. 0.048M Hepes-NaOH ph 7.0, 0.096M NaCl, 9.5% Glycerol, 0.96mM
EDTA)

with

or

without

0.2mM

of

the

AMPK

substrate,

SAMS

peptide

(HMRSAMSGLHLVKRR; see (79) (113)). All samples, both with and without SAMS,
were run in duplicates. A set of blanks, in which no protein was added, was also included
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in the assay. 3X of an ATP solution (5mM MgCf, 0.2mM ATP, [32P]ATP (New England
Nuclear, Boston, MA)) was added to the kinase assay mixture. The assay continued for
10 minutes at 37° C.

Aliquots (15A) of the reaction mixture were then spotted on

Whatman filter paper (P81) and the filter papers were dropped into cold 150mM
phosphoric acid to stop the reaction.

The filter papers were washed 4 times for 10

minutes each with cold 150mM phosphoric acid and then once for 20 minutes with
acetone. After the filter papers had dried, they were placed into scintillation vials with
5ml scintillation fluid and subjected to scintillation counting.

Statistics
Results were determined using the student’s t test and are presented as means + SEM.
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Results

Enrichment of AMPK in PEG precipitated fractions: In order to partially enrich
AMPK in heart homogenates, protein from each PEG precipitated fraction (2.5-6%, 610% and the 10% supernatant) was immunoblotted for total AMPK (see Figure 1A). A
28-fold increase in AMPK levels was seen in the 2.5-6% PEG fraction as compared to the
6-10% PEG fraction and the 10% supernatant PEG fraction (p < 0.0005 vs. 6-10% PEG
fraction and p < 0.0005 vs. 10% supernatant PEG fraction). These findings suggest that
the majority of AMPK is present in the 2.5-6% PEG-precipitated fraction with only
minor amounts appearing in the remaining PEG fractions.

Enrichment of AMPKK activity in PEG precipitated fractions: In order to enrich
AMPKK in heart homogenates, protein from each PEG precipitated fraction (2.5-6%, 610% and the 10% supernatant) was incubated with recombinant ai AMPK subunit.
Incubation samples were then immunoblotted for pThr1/2 and total AMPK (Figure IB).
A 22-fold increase in Thr “ phosphorylation of the recombinant a-1 AMPK subunit was
seen when the 6-10% PEG fraction is included in the incubation as compared to the 2.56% PEG fraction and the 10% supernatant PEG fraction (p < 0.0005 vs. 2.5-6% PEG
fraction and p < 0.0005 vs. 10% supernatant PEG fraction). These results clearly suggest
that the majority of AMPKK is present in the 6-10% PEG-precipitated fraction.
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protein extract (25 Mg) from the 2.5-6% PEG fraction, 6-10% PEG fraction and the supernatant from the 10% fraction (n=3) in 25
pi of kinase buffer. Incubations were then immunobbtted using pThrl72 and pan-a-AMPK antibodies to show the amount of
phosphoiylated recombinant <xl AIvIPK as a measure of AMPKK activity (+p < 0.0005 vs. both 2.5-6% and >10%).

Sflrichmertf of AMPKK activity in Heart Extracts. 10 pmol of recombinant cd AMPK subunit was incubated for 10 minutes with
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Effects of time and concentration on AMPKK activity: We next examined the effects
of time and concentration on AMPKK activity in order to obtain the optimal conditions
under which to assess the effects of ischemia on AMPKK activity. In the investigation of
the time dependence of AMPKK activity, 6-10% PEG precipitated heart protein was
incubated with recombinant heterotrimeric AMPK for 10, 20 and 60 minutes. Incubation
samples were then immunoblotted for pThr

and total AMPK (Figure 2A).

As

incubation time increased, pThr “ levels on the recombinant heterotnmenc protein also
increased, with the steepest part of the curve appearing between 10 and 20 min, thereby
suggesting that experiments involving AMPKK would be best performed at times within
this range.
Subsequently, the concentration dependence of AMPKK activity was examined
by incubating recombinant heterotrimeric AMPK with 5 pg, 10 pg, and 25 pg of 6-10%
PEG precipitated heart protein and then immunoblotting the incubation samples for
pThr172 and total AMPK (Figure 2B). As the concentration of 6-10% PEG precipitated
protein increased, the level of pThr “ increased as well in a nearly linear fashion. It was
determined that 10 pg was an optimal concentration at which to perform further AMPKK
studies since it was in the linear part of the curve, it produced adequate phosphorylation
at the Thr172 site, and it did not require excessive amounts of protein.
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25 Mg of AMPKK in the 6-10% PEG fraction for 10 min in 25 pi of kinase buffer (n=3). Incubations were immunobbtted
using pThrl72 and a-AMPK antiboilies (+p < 0.01 vs. 5pg AMPKK). Immunoblots were quantified using densitometry.
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Effects of in vitro ischemia on AMPK phosphorylation and activity in the heart:
AMPK activity has been recently shown to be cardioprotective during ischemia (150),
although the mechanism for this effect and the role that AMPKK plays remains unclear.
Having obtained a basic understanding of some of the characteristics of AMPKK activity,
we were now able to investigate the effects of global low-flow ischemia on the level of
AMPKK activity as measured by phosphorylation of Thr

. In order to provide an index

of AMPK activity in the intact heart during in vitro ischemia, we compared the degree of
endogenous AMPK phosphorylation at Thr
during both control and ischemic conditions.

as well as endogenous AMPK activity
Our results demonstrated a 2.6-fold

increase (P < 0.002) in pThr ‘ levels in the ischemic heart (Figure 3A) and a 3.4 fold
increase (p < 0.01) in AMPK activity as measured by the SAMS kinase assay (Figure
3B). Increased Thr “ phosphorylation of AMPK may reflect either increased AMPKK
activity, or decreased phosphatase activity during ischemia.
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Kinetics of AMPK activation during in vitro ischemia: Having determined that
ischemia does indeed activate AMPK, we next examined the effects of varying time
courses of in vitro ischemia on the degree of AMPK Thr " phosphorylation and kinase
activity. Hearts were subjected to 1 or 20 minutes of control perfusion or to 1, 2, 5, 10 or
20 minutes of global low-flow ischemia, before being homogenized and precipitated into
PEG fractions.

The 2.5-6% PEG fraction, containing endogenous AMPK, was then

immunoblotted for pThr17' and total AMPK levels (Figure 4A) and the SAMS kinase
assay was performed to assess for AMPK activity (Figure 4B) (SAMS kinase assay was
performed by Ji Li PhD.).

Global ischemia resulted in a significant increase in Thr172

phosphorylation (p < 0.05) with maximal Thr

phosphorylation observed after 5

minutes (Figure 4A). Endogenous AMPK activity was also found to be increased 2- to 3fold (p < 0.01) during global ischemia, with maximal activity observed after 5 minutes,
thereby mirroring the observed increase in Thr172 phosphorylation (Figure 4B). Based on
these experiments, it was determined that AMPKK activation was very rapid in this
ischemic model.

&

was immunoblotted withpThrl72 and pan-a-AMPK antibodies. Immunoblots were quantified using densitometry (p < 0.05
vs control). Panel B - AMPK kinase activity: Endogenous AIvIPK act nab/ was measured using the SAMS kinase assay with
10|jg of control and ischemic AMPK from the 2.5-6% PEG precipitate (* p < 0.01 vs. 1 min control, + p < 0.01 vs 20 min
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Effects of in vitro ischemia on AMPKK activity: In order to directly examine the
possibility that AMPKK activity is increased by in vitro ischemia, 6-10% PEGprecipitated protein from both control and ischemic tissue was incubated with either the
recombinant ai AMPK subunit or recombinant heterotrimeric AMPK (Figure 5A, 5B).
The incubations were then lmmunoblotted for pThr

and total AMPK. Under ischemic

conditions, Thr “ phosphorylation was increased 1.5-fold (P < 0.04) on the recombinant
a-1

AMPK subunit (Figure 5A) and 2-fold (P < 0.00002) on the recombinant

heterotrimeric AMPK (Figure 5B) during ischemia as compared to control conditions.
Together, these results indicate that in vitro
activator of AMPKK.

global ischemia acts as a physiological
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Effects of in vivo ischemia on AMPK and AMPKK activity: The same experiments
were performed using tissue from hearts subjected to regional ischemia by left coronary
occlusion.

We first examined endogenous AMPK Thr

phosphorylation as well as

endogenous AMPK activity in control and ischemic homogenates. We found that there
was a 2-fold increase (p < 0.03) in pThr

levels in the ischemic heart (Figure 6A) and a

3-fold increase (p < 0.01) in AMPK activity (Figure 6B).

Subsequently, we incubated

AMPKK protein from the 6-10% PEG fraction with either the recombinant oq AMPK
subunit or the recombinant heterotrimeric AMPK (Figure 7A, 7B).

Our results

demonstrated an insignificant increase (p < 0.15) in Thr1/2 phosphorylation of the
recombinant a-1 AMPK subunit (Figure 7A); however there was a 1.3-fold increase (p <
0.04) in pThr172 on the recombinant heterotrimeric AMPK (Figure 7B) during ischemia in
comparison to control hearts. These results suggest that regional ischemia produced via
ligation of the left coronary artery serves to increase AMPKK activity, although to a
lesser extent when compared to the increase in AMPKK activity observed during in vitro
ischemia.

<xf

TO

CO

AijAipe HdlNV

CD
'§

<x»

<o

o
.a
13

<1>
O
■«—«
0>
o

¥
«
a

i
s

5
P3,

J*
w
*3
C
JS
w
.S3

I

.s

a

*0

e

vo

ligation of the LCA for 10 minutes (n=6) or to control conditions (sham operation) (n=7). Panel A - ThrI72
Phosphorylation: Phosphoiylated and total AMF'K in the 2.5-6& PEG fraction was immimoblotted with pThrl72 and pan-ceAMF'K antibodies. Western blots were quantified using densitometry (p < 0.04 vs control). Pane! B - AWPK kinase
activity: Endogenous AMF’K activity was measured using the SAMS kinase assay with 10 Mg of control and ischemic AMF’K
from the 2.5-6% PEG precipitate (+ p < 0.01 vs. control).
40

41

:

;. .

O
*3
OC
C_>

t

i
ii
1I

1tschemi,
(n=7)

Ischemia

m

F ■
+

*—
!
1

Control

S -3 £
? 3 2
«J A « CN
C—

1

5
1

N

s~\
ao
.rII

'S
5 H
<X> *—•
uc ?3
o
&
43 X

■I? I
o

•g
§
® 8 .9

m
id
4> H

tj

C3

1

< S

,
^—v

o C--

H

4>
»

o

V
a

r-4
P

0>

- 24 !L -»—

■s
v>

^!W MHdW

oo

o>

S
g 0 £ g
73•o> o
a
o>
y*-< x-:.
1
»—<
r-*-«
Vi
~ g
c2 53 g fc "H
r£ O
3^

P *■>-»

• r;

,'S

Ischemia

o g Cj o

<T3
C
fc f-'
r- <U

j:

||

c

o •w

£
5 j§ £q J■1> ’rr
<u
*c3 o
O « 3 Q
R •S O
B a: ~ V
1 °
S3 ^ O
£
w 8 ^
Du 3. +
.a w
O ^
o

■i> o
.sV fi
3a
2
S3 S
s
Vi

M
*Jj

o

Control

C

.5
<o
if

o c
w

o

<^“<1
n*

ZT r*
CL

u.

5? x;

^wvmwiv

sS3

<

O

J5oo
P

•x>

>-4

V

-I***"* $"$

3 P-t
a> *
'S o
2
«
w >i
•TS «l>
C< rP .3 S*^
o O
< 'ip ;i> JD
o
3 >i> CL "S
o s
*5 &’ 73 w W
cu
^
*» r
v-» a
I
5?
t-* o
o <
c. « J*
■••o
I" a I 32 <3
»•*■■■<
i

. H-

a
2
«

CL

42

Discussion
The overall aim of this study was to examine the effect of ischemia on the
AMPK-AMPKK cascade in the heart.

Our initial results demonstrated that ischemic

conditions resulted in increased Thr

phosphorylation along with increased kinase

activity of AMPK, thereby reaffirming previous research that ischemia acts as an
activator of AMPK (79) (80) (81). This finding is consistent with the notion that AMPK
is activated by physiological environments associated with metabolic stress, including
exercise (60), hypoglycemia (82), hypoxia (83), and heat shock (98).
While it has been presumed that the activation of AMPKK, the upstream kinase of
AMPK, is responsible for the phosphorylation of AMPK during metabolic stress, the
scientific literature on this subject has been limited and has not supported this theory.
Indeed, initial studies have indicated that AMPKK was constitutively active in
insulinoma cell lines (136), liver (146) and skeletal muscle (147). In order to study the
question of the regulation of AMPKK, we developed a novel enzymatic assay with which
we were able to show a significant increase in AMPKK activity during in vitro and in
vivo ischemia in myocardial tissue.

Our results represent the first demonstration, in any

tissue, of the activation of AMPKK by a physiological stimulus, thereby suggesting that
increased AMPK phosphorylation during metabolic stress is due to the increased activity
of AMPKK as opposed to the inhibition of phosphatase activity, or to changes in the
structure of AMPK that may have led to an increased ability of the protein to become
phosphorylated, or to autophosphorylation by AMPK itself.
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Development of an AMPKK Assay
There were several experimental parameters that needed to be considered when
devising an AMPKK assay, such as enriching the kinase from myocardial homogenates,
establishing the concentration and time dependence of the enzyme, understanding the
kinetics of the AMPK-AMPKK reaction in the heart, and determining appropriate
substrates to use in the assay. Early research that had examined liver AMPKK found that
AMPKK

activity

could

be

enriched

using

protein

fractionation

methods

with

polyethylene glycol precipitation (67), thereby providing a starting point for the
development of the AMPKK assay detailed herein. Our results clearly demonstrated that
heart AMPKK was enriched in the 6-10% PEG fraction.

Furthermore, the virtual

absence of AMPKK activity observed in the 2.5-6% PEG fraction and the 10% PEG
supernatant suggests that we were able to enrich AMPKK without losing AMPKK
activity in other PEG fractions during the enrichment process.

It should also be noted

that AMPK was found to be present exclusively in the 2.5-6% PEG fraction. The fact
that AMPK and AMPKK activity were enriched in different PEG fractions was
important, since it guaranteed that endogenous AMPK would not be present and thereby
would not introduce background signal during experiments that used the recombinant
heterotrimeric AMPK as a substrate.

There was no possibility of overlap with

endogenous AMPK signal using the other substrate, the recombinant cci AMPK subunit,
since it migrated more slowly during SDS-PAGE because of a higher molecular weight.
After achieving the enrichment of AMPKK, it was next necessary to detail the
optimal experimental conditions for the assay. Specifically, we studied the effects of the
duration of the assay as well as the effects of the amount of AMPKK protein on AMPKK
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activity. Our results allowed us to choose parameters that ensured a linear relationship
between these variables (amount of AMPKK or the time course of the assay) and the
observed AMPKK activity, as well as confirming that the substrate would not be a
limiting factor for the assay.
Further experiments were performed in order to examine the time course of
AMPK activation during low-flow ischemia in the heart.

Our results clearly

demonstrated that AMPK is activated early on during ischemia and remains significantly
activated after 20 minutes, thereby indicating that a relatively short duration of ischemia
is sufficient to produce AMPK activation.

Such results would suggest that AMPKK

activity is rapidly activated in a similar fashion; however, the question arises as to
whether AMPKK follows a prolonged course of activation similar to that of AMPK, or
whether AMPKK may instead experience a transient peak of activation at an early time
point during ischemia and then return to baseline levels of activity at later time points.
Recent research from our laboratory has reported significant AMPK activation after 30
minutes of ischemia that persists during 30 minutes of reperfusion in perfused mouse
hearts (150).

These findings would suggest that AMPKK activity is consistently as

opposed to briefly elevated during ischemia. Additional experiments performed in our
laboratory by Dr. Ji Li have confirmed this theory by demonstrating early and persistent
activation of AMPKK after 20 minutes of ischemia (Appendix A - Figure 1) (141).
An important component of an assay examining enzymatic activity is the
utilization of an appropriate substrate.

We were fortunate to be able to obtain two

different recombinant AMPK substrates through scientific collaboration with researchers
at Dartmouth University and from Zurich. This study initially utilized a recombinant aj
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AMPK subunit, which is a truncated synthetic version of the ai subunit containing amino
acids 1-312 with a N-terminal maltose binding protein, that had been used in other
studies in order to assess AMPKK activity in insulinoma cells (136). Since this truncated
recombinant ai subunit contained the Thr

phosphorylation site, we believed that it

might be a suitable substrate with which to assess AMPKK activity as a measure of
Thr172 phosphorylation. Initial experiments demonstrated that this substrate was readily
phosphorylated by AMPKK.

We then obtained a more physiologic substrate, a

recombinant heterotrimeric otiPiyi AMPK protein.

Since AMPK is a heterotrimeric

protein, it was highly possible that AMPK phosphorylation by AMPKK is affected by the
tertiary structure of the AMPK heterotrimeric complex.

Subsequent experiments were

performed using the recombinant heterotrimeric ctipiyi AMPK protein.

While the

findings were largely similar in experiments using the recombinant heterotrimeric oti J3iyi
AMPK protein and the recombinant oq AMPK subunit, the experiments involving the
recombinant heterotrimeric aiPiyi AMPK protein produced more consistent results.
One additional possible explanation for the observed difference in results is that
the presence of the regulatory y subunit in the recombinant heterotrimeric AMPK protein
may have resulted in the steric hindrance of phosphatases, thereby leading to a decreased
susceptibility of the catalytic a subunit to dephosphorylation.

Without such steric

hindrance, the recombinant oq AMPK subunit may have been more vulnerable to
phosphatase activity, thus leading to less consistent results.

If this hypothesis were

accurate, we would have expected to see less Thr “ phosphorylation across both control
and ischemic samples during experiments using the recombinant cti AMPK subunit as
compared to experiments using the recombinant heterotrimeric aiPiyi AMPK protein.
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Nevertheless,

overall

level

of Thr

172

phosphorylation was

comparable

between

experiments using either the recombinant oti AMPK subunit or the recombinant
heterotrimeric aiPiyi AMPK protein, thereby suggesting that variable results obtained
using the recombinant cti AMPK subunit were not likely due to phosphatase action.
Certainly, the presence of the |3 and y subunits may have been responsible for the
more consistent results seen during experiments utilizing the recombinant heterotrimeric
aiPiyi AMPK protein. In particular, the y subunit has been implicated in binding AMP,
which results in a conformational change of the kinase that leads to greater Thrl/2
phosphorylation (55), probably due to the fact that an AMP-AMPK complex provides a
better substrate for AMPKK (78).

With the heterotrimeric AMPK protein, AMP may

have been able to complex with AMPK to produce a better site of action for AMPKK,
thereby magnifying the effects of the activated AMPKK.

While this is a theoretical

explanation for the observed effects, the experiments were performed in the absence of
AMP in that no AMP was added to the incubation buffer and carry over of AMP from
heart homogenate in the 6-10% PEG fraction was likely minimal, thereby making this
hypothesis less likely.
With regards to the recombinant heterotrimeric aiPiyi AMPK protein as a
substrate for the AMPKK assay, it should be noted that multiple isoforms of AMPK
subunits exist.

In fact, the

gli

isoform is predominant in myocardial tissue.

Thus,

although the recombinant heterotrimeric aiPiyi AMPK protein was an excellent substrate
for the AMPKK assay, it should be noted that findings related to this recombinant
heterotrimeric aiPiyi AMPK protein are slightly limited as it is not the dominant isoform
in heart (55).

A recombinant heterotrimeric a2Piyi AMPK protein has since become
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available, and recent studies in our laboratory, performed by Dr. Ji Li, have demonstrated
results using the recombinant heterotrimeric 0C2P1Y1 AMPK protein that are similar to the
results described herein using the recombinant heterotrimeric ctiPiyi AMPK protein
(Appendix A - Figure 2) (141).
Thus, this study was able to develop an effective assay with which to examine
AMPKK activity. This assay should serve as a useful research tool in the further study of
AMPKK regulation in the heart as well as in other tissues.

Ischemia is an activator of AMPKK
The predominant mechanism responsible for the increased level of Thr172
phosphorylation on heart AMPK observed during ischemia has been previously
unknown.

The results presented herein suggest, for the first time, that ischemic

conditions do increase AMPKK activity as measured by increased levels of Thr1,2
phosphorylation and increased kinase activity of the recombinant heterotrimeric protein,
thereby challenging the prior notion that AMPKK is constitutively active (136).
Two different experimental ischemia preparations were used in this study.

We

utilized in vivo regional ischemia in order to examine AMPKK activity under integrated
physiologic conditions; however, while using the in vivo protocol, we found that control
tissues sometimes displayed increased baseline AMPKK activity.

Such findings led to

the speculation that AMPKK is extremely labile, such that even a short course of
ischemia, as produced during the time when the control heart was excised and frozen,
would lead to increased AMPKK activity. Therefore, it was determined that it would be
advantageous to utilize an in vitro tissue preparation protocol in which the tissue could be
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immediately frozen when the control and ischemic protocol ended.

Furthermore, our

laboratory has recently demonstrated that AMPK plays a critical role in preventing
myocyte apoptosis after in vitro low-flow ischemia (151), thus increasing our interest in
using this experimental ischemic model to assess AMPKK activity.
There

are

several

limitations that need to

be recognized when making

generalizations using results from in vitro experiments about AMPKK activity.

First,

global as opposed to regional ischemia is produced during the in vitro protocol, which
does not mimic the typical clinical situation of coronary artery disease.

Also, the

neurohumoral activation and influence of other substances, such as catecholamines or
angiotensin II that may affect cardiac energy metabolism in vivo, are absent in an in vitro
tissue preparation. Lastly, a heart perfused under in vitro conditions experiences a lower
workload than a heart in vivo, thereby reducing the need for increased energy metabolism
and subsequently potentially decreasing the degree of AMPK activation.

In order to

circumvent the issue of a decreased workload, the working heart model was utilized as it
produces a greater workload than the Langendorf model of in vitro retrograde perfusion.
The findings presented herein, that AMPKK activity is increased by ischemia, are
directly contradictory to the previous belief that AMPKK is constitutively active (136).
This discrepancy may be explained by the differences in experimental methodology
employed by Hamilton et al (136) and this current study. Firstly, Hamilton et al (136)
employed an insulinoma cell line as opposed to the whole heart tissue preparation used in
this study. Certainly, in a whole tissue preparation, multiple factors, including cell-to-cell
interaction and synchronous contractility, can influence energy metabolism, and these
additional factors may be involved in regulating AMPKK activity. Also, Hamilton et al
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(136) incubated the synthetic AMPK substrate with crude cell lysate as opposed to
enriching AMPKK through PEG fractionation.

It is unknown what other proteins,

specifically phosphatases, may have been present in the cell lysate and how those
proteins might have affected the levels of Thr

phosphorylation observed. Furthermore,

Hamilton et al (136) used only the recombinant ai AMPK subunit as a substrate, which is
likely not the optimal substrate to study the subtle differences in AMPKK activity under
control and experimental conditions as has been previously discussed.
This study raises the question of how ischemia activates AMPKK on a molecular
basis.

Initial experiments had suggested that increased levels of AMP, such as those

produced during ischemia (79), might serve to activate AMPKK (78).

Using the

methodology developed in this study, subsequent experiments, performed in our
laboratory by Dr. Ji Li, were developed to address the effects of AMP on AMPKK
activation during myocardial ischemia. The results of these experiments involving AMP
have been subsequently published in conjunction with the experiments described herein
(See Appendix B) (141).

AMPKK was incubated with a series of substrates (the

recombinant ai AMPK subunit, a recombinant heterotrimeric AMPK protein containing
a y subunit with the R70Q mutation, which decreases the y subunit’s ability to bind AMP,
and a recombinant wild-type heterotrimeric ctiPiyi AMPK protein) in the presence or
absence of AMP.

AMP had no effect on AMPKK activity as assessed by unchanging

levels of Thr172 phosphorylation from both control and ischemic samples when the
recombinant isolated ai AMPK subunit or the R70Q mutated AMPK was used as a
substrate (Appendix A - Figures 3 and 4) (141). However, similar experiments using the
recombinant heterotrimeric oiiPiyi AMPK protein as a substrate, demonstrated increased
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levels of Thr ‘ phosphorylation by AMPKK in the presence of AMP (Appendix A Figure 5) (141). These results suggest that AMP acts to make AMPK a better substrate
by interacting with the y subunit, but has no direct effect on AMPKK activity.
Interestingly, when AMPKK activity was studied in the presence of ATP, there was no
change in AMPKK activity when the recombinant oti AMPK subunit was used as a
substrate; however, when the recombinant heterotrimeric ciiPiyi AMPK protein was used
as a substrate, AMPKK activity was found to be decreased by increasing levels of ATP,
thereby suggesting that ATP acts to indirectly inhibit AMPKK activity by transforming
AMPK into a less suitable substrate for phosphorylation (See Appendix A - Figure 6)
(141).

These results, when taken together, suggest a model of the AMPK-AMPKK

cascade, in which ischemia activates AMPKK through an AMP-independent mechanism
and AMP and ATP function to either promote or inhibit respectively the ability of AMPK
to be phosphorylated by AMPKK in the heart (Figure 8).

Ischemia

p'
Increase Glucose Uptake

''A
Decrease Myocyte Apoptosis and Injury

Figure 8: Model of AMPKK and AMPK activation by Ischemia: Ischemia increases AMP levels
and decreases ATP levels. AMP then binds the y subunit of AMPK, leading to an AMPK-AMP
complex. The AMPK-AMP complex is a more suitable substrate for AMPKK to phosphorylate at the
Thr1"2 site, thereby leading to the activation of AMPK. Ischemia also acts to activate AMPKK by a
mechanism that is independent of AMP.
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Recent research, published in January 2005, has also demonstrated that AMPKK
activity is increased during myocardial ischemia (142), and serves to further confirm the
findings of this thesis.

Methodology similar to the methods described here was

employed, although a 5% PEG supernatant (that may have contained endogenous AMPK
activity) as opposed to a 6-10% PEG precipitant was utilized for AMPKK enrichment
and only the recombinant cp subunit was used as a substrate (142). These authors also
suggested that heart AMPKK was activated by ischemia in the absence of changes in
AMP concentration (142). This conclusion was based on cardiac tissue analysis of the
cellular content of AMP using high performance liquid chromatography (HPLC). Since
most AMP is bound to cellular proteins, the free cytosolic AMP is present at much lower
concentrations than the total AMP (i.e. pM versus near mM), and is also likely
responsible for regulating AMPK activity. Furthermore, studies have shown that AMPK
is activated in the intact heart by minor changes (i.e. lpM) in the concentration of free
AMP (151). Since HPLC measures total levels of AMP, it seems likely that the methods
used by these authors were not sensitive to support the conclusion that AMP
concentrations do not change in the ischemic heart. Thus, while the study by Altarejos et
al (142) confirm our results that AMPKK is activated by myocardial ischemia, they do
not provide convincing proof that the mechanism by which AMPKK is activated is
independent of AMP.
Other physiologic activators of AMPK that do not appear to rely on AMP as a
molecular mediator do exist. Researchers have found that hyperosmotic stress and
metformin both result in an increase in Thr " phosphorylation and increased AMPK
activity in the absence of any detectable change in AMP levels (92).

Further studies
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revealed that neither phosphatidylinositol 3-phosphate kinase, protein kinase C, mitogenactivated protein (MAP) kinase kinase, nor p38 MAP kinase were involved in the
activation of AMPK by hyperosmotic stress (92).

The here-to-uncharacterized AMP-

independent mechanism by which hyperosmotic stress and metformin activate AMPK
may or may not be the same mechanism by which AMPKK is activated. Further research
is needed to identify and characterize the mechanisms responsible for AMPKK activation
in the heart.

Other Phosphorylation Sites on AMPK
This study concentrated on the phosphorylation of Thr172, which is the critical
activating site on the a catalytic subunit of AMPK (53) (54).
that there are two other sites (Thr

, Ser

) besides Thr

Recent research has found

present on the a subunit (143),

as well as multiple sites on the (3 subunit (Ser24/25, Ser108, Ser182) that are phosphorylated
by upstream kinases (152).

Site specific mutagenesis of Thr258 and Ser485 revealed no

difference in AMPK activity, thereby suggesting that these sites are not important for
activation of AMPK. Furthermore, examination of the amino acid sequence surrounding
Thr258 and Ser487 reveals sequences significantly different from that surrounding Thr172,
leading researchers to speculate that two separate upstream kinases are responsible for
phosphorylating Thr172 and Thr258/Ser485 (143). Thus, it seems likely that ischemia has a
primary effect on the AMPKK that is primarily responsible for regulating Thr172
phosphorylation, while other upstream kinases, which are not involved in Thr172
phosphorylation, may not be similarly affected by ischemia or other enviromnents
involved in modulating AMPK activity.
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Other Upstream Kinases of AMPK
This study focused on the physiologic activation of upstream kinase activity of
AMPK, which has been generically termed AMPKK; however, the molecular identity
responsible for the kinase activity observed in this study is still unknown. Early studies
in liver have shown that Ca" /calmodulin (CaM)-dependent protein kmase I kinase
(CAMKIK) is able to activate AMPK, although this study clearly demonstrated that other
proteins besides CAMKIK existed with greater specificity and activity for AMPK
activation (78).
More recent research in yeast has identified three upstream kinases, Paklp, Tos3p
and Elmlp, responsible for phosphorylating and activating Snfl kinase, the yeast
analogue of AMPK (144).

Such findings led to the identification of a mammalian

relative of Paklp, Tos3p and Elmlp, known as LKB1, a kinase that shares a similar
catalytic domain as the three upstream yeast kinases (144). LKB1 is a tumor suppressor
protein involved in the inhibition of cellular propagation. Mutations in the LKB1 gene
have been found to cause Peutz-Jeghers syndrome, an autosomal dominant condition
associated with hamartomatous polyps of the colon and small intestine, melanotic
nodules of lips and hands as well as an increased risk for malignancies in the stomach,
breast and ovary (145).

When isolated, LKB1 was found to phosphorylate AMPK at

Thr172 and activate the protein kinase (144) (146).

Furthermore, when LKB1 was

removed from purified extracts of rat liver containing AMPKK activity, the extracts were
no longer able to phosphorylate and activate AMPK (146).
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The role of LKB1 in the heart is unclear at this time. Recent preliminary studies
in our laboratory have shown that, although LKB1 is present in the heart, it is found in
PEG

fractions

that

do

not

demonstrate

AMPKK

activity

(unpublished

data).

Furthermore, additional research has demonstrated that, while AMPKK activity is
increased during ischemia, there is no difference in immunoprecipitated LKB1 activity in
ischemic myocardium as compared to control tissue (142).

Taken together, these

observations seem to suggest that another protein besides LKB1 is responsible for the
AMPKK activity observed during cardiac ischemia. Nevertheless, it has been difficult to
assess the activity of LKB1 in vitro due to the dissociation of LKB1 from STRAD and
M025, which are two modifier proteins that form a functional complex with LKB1 (146)
and may be necessary for LKB1 activity.
While it seems likely that LKB1 may not be responsible for the AMPKK activity
described herein, LKB1 does seem to share the characteristic with heart AMPKK of
being unresponsive to AMP. Studies have demonstrated that skeletal muscle LKB1 was
unaffected by AICAR or exercise (147) and that liver LKB1 activity was unaltered by
AMP (146).

These results regarding LKB1 activity are consistent with findings that

AMP does not increase AMPKK phosphorylation of either the recombinant oti subunit or
of a recombinant AMPK with the R70Q mutation in the y subunit (141).

Further

investigation is needed to understand the physiological environments responsible for
activating LKB1 as well as to define the role of LKB1 in the heart.
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Conclusion
In summary, this study is the first to demonstrate that AMPKK is not
constitutively active, but is indeed activated by ischemia, thereby suggesting that the
regulation of Thr

phosphorylation of AMPK is mediated by upstream kinases. Further

experiments are needed to define the molecular identity of heart AMPKK and to study
the molecular mechanism by which AMPKK is activated. By elucidating the regulation
of AMPKK, a greater understanding of AMPK activation can be obtained
As research continues into the upstream regulation of AMPK, scientists have been
investigating the large-scale physiological role of AMPK through the utilization of mice
genetically engineered to be deficient in AMPK.

AMPK-deficient mice demonstrate

multiple defects in metabolism, including glucose intolerance, decreased sensitivity to
insulin in muscle,

decreased glycogen in

skeletal muscle

(148)

and increased

catecholamine production (149). The variety of metabolic irregularities produced in an
AMPK-deficient organism illustrate the complex role that AMPK plays in the regulation
of metabolic processes. Future research, employing genetically altered mice and other
technological advances, will serve to further clarify AMPK’s function as a cornerstone in
the regulation of metabolism and perhaps point to possible treatments for diseases of
metabolic dysfunction and the ischemic heart.
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Figure Al; Kinetics of AMPKK activation in the in vitro ischemic heart:
AMPKK activities were assessed in the working heart model after control or
low-flow ischemic perfusions, cqfjf^ rAMPK (5pmol) was incubated with
heart AMPKK (10 pg) for 10 minutes and then immunoblotted withpThi172
and pan-a AMPK antibodies to measure AMPKK activity. Immunobbts
were quantified using densitometry. (* p < 0.05 vs 1 minute control; + p <
0.01 vs 20-minute control). Values are means + SE for 3 independent
experiments.
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Figure A2: AMPKK activation in the in vitro ischemic heart using
recombinant heterotrimeric
AMPK protein as substrate. Rat hearts
were perfused using the working heart model under control (ri=3) and towflow (15%) ischemic conditions (n=3). Recombinant heterotrimeric
AMPK were incubated with control and ischemic heart AMPKK from the 610% PEG precipitate for 10 minutes in 25 pi of kinase buffer. Incubations
were then immunob lotted with pThr172 and pan-coAMPK antibodies and
quantified using densitometry. Values are means + SE for 3 independent
experiments (* p < 0.01 vs control).
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with AMPKK, substrates were immunobbtted with pThr172 and pan-a AMPK antibodies and then relative phosphorylation was
quantified using densitometry. Panel B: The activity of the R70Q mutated recombinant a^^AMPK were then measured using
the SAMS peptide as a substrate. The AMP concentration m Panel B refers to that present during incubations with AMPKK.
Values are means + SE for 3 independent experiments (* p < 0.01 vs control group).
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Appendix B: Reprint of Journal Article

Dual Mechanisms Regulating AMPK Kinase Action in
Ischemic Heart

the

Suzanne J. Baron,* * Ji Li,* Raymond R. Russell III, Dietbert Neumann, Edward J. Miller,
Roland Tuerk, Theo Wallimann, Rebecca L. Hurley, Lee A. Witters, Lawrence H. Young
Abstract—AMP-activated protein kinase (AMPK) is emerging as an important signaling protein during myocardial
ischemia. AMPK is a heterotrimeric complex containing an a catalytic subunit and /3 and y regulatory subunits.
Phosphorylation of Thr172 in the activation loop of the a subunit by upstream AMPK kinase(s) (AMPKK) is a critical
determinant of AMPK activity. However, the mechanisms regulating AMPK phosphorylation in the ischemic heart
remain uncertain and were therefore investigated. In the isolated working rat heart, low-flow ischemia rapidly activated
AMPKK activity when measured using recombinant AMPK (rAMPK) as substrate. The addition of AMP (10 to
200 jtimol/L) augmented the ability of heterotrimeric ct,/3,-y 1 or a2^,yl rAMPK to be phosphorylated by heart AMPKK
in vitro, whereas physiologic concentrations of ATP inhibited rAMPK phosphorylation. However, neither AMP nor
ATP directly influenced AMPKK activity: they had no effect on AMPKK-mediated phosphorylation of rAMPK
substrates lacking normal AMP-binding y subunits (isolated truncated a/'312 or a^yl rAMPK containing an R70Q
mutation in the y{ AMP-binding site). Regional ischemia in vivo also increased AMPKK activity and AMPK
phosphorylation in the rat heart. AMPK phosphorylation could also be induced in vivo without activating AMPKK:
AICAR infusion increased AMPK phosphorylation without activating AMPKK; however, the AMP-mimetic AICAR
metabolite ZMP enhanced the ability of heterotrimeric rAMPK to be phosphorylated by AMPKK. Thus, heart AMPKK
activity is increased by ischemia and its ability to phosphorylate AMPK is highly modulated by the interaction of AMP
and ATP with the heterotrimeric AMPK complex, indicating that dual mechanisms regulate AMPKK action in the
ischemic heart. (Circ Res.

2005;96:337-345.)

Key Words: AMP-activated protein kinase a AMPK kinase u ischemia

A

MP-activated protein kinase (AMPK) regulates energy

creases in intracellular AMP. However, AMPK is also phos¬

generating metabolic and biosynthetic pathways during

phorylated through AMP-independent pathways during os¬

physiologic and pathologic cellular stress. AMPK activation

motic stress16 and metformin17 or leptin18 stimulation.

stimulates fatty acid oxidation,1 promotes glucose trans¬

Activation of AMPK is very sensitive to an increase in the

port,2-3 accelerates glycolysis,4 and inhibits triglyceride5 and

intracellular concentration of AMP, which promotes its allo¬

protein synthesis.6 By increasing ATP synthesis and decreas¬

steric activation and phosphorylation.19-20 Phosphorylation of

ing ATP utilization, AMPK functions to maintain normal

the a subunit Thr'72-activadng site is mediated by one or more

cellular energy stores during ischemia. Chronic activation of

upstream kinases, termed AMPK-activating protein kinases

AMPK also phosphorylates transcription factors altering gene

or AMPKK(s).21 AMP increases liver AMPKK(s) activity

expression7 and modulates muscle mitochondrial biogenesis.3

through binding to the AMPK y subunit, which renders

AMPK is a heterotrimer consisting of an a catalytic

AMPK a better substrate for AMPKK, and by direct activa¬

subunit and (5 and

y regulatory subunits. The primary

tion of AMPKK by AMP.22 However, recent findings chal¬

mechanism responsible for AMPK activation involves phos¬

lenge the notion that AMP has a direct effect on AMPKK23

phorylation of the Thr172 residue located within the activation

and have also raised the possibility that AMPKK is constitu-

loop of the a catalytic subunit.9 Additional phosphorylation

tively active.24

sites have been identified on the a and |3 subunits, but their

The physiological mechanisms responsible for the regula¬

functional roles remain uncertain.10-11 Activation of AMPK

tion of AMPKK in the heart remain uncertain. The aims of

during myocardial ischemia,'-12 exercise,13 hypoglycemia,14

this study were to assess whether AMPKK is activated by

and hypoxia15 is associated with ATP breakdown and in¬

ischemic stress and the extent to which AMP and ATP
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modulate heart AMPKK action. The results indicate that heart

AMPKK Assay

AMPKK is activated by ischemia, but that it is not directly

Heart AMPKK activity was assessed by measuring the AMPKK-

affected by either increases in AMP or decreases in ATP
concentration. Instead, AMP augments and ATP inhibits the

induced Thr172 phosphorylation of rAMPK substrates in vitro. Initial
experiments demonstrated that AMPKK activity was present almost
exclusively in the 6% to 10% PEG fraction (see Results). To assess

action of AMPKK to phosphorylate and activate the AMPK

AMPKK activity, protein (10 jug) from the 6% to 10% PEG fraction

a subunit by interacting with the heterotrimeric AMPK

was incubated with

complex.

(N-terminal maltose binding protein),34 or 5 pmol of a£,/3,-yI rAMPK

10 pmol of truncated a,1"2 fusion protein

containing an R70Q mutation in the y, AMP-binding site, wdd-type
01,13,71, or a2j3,yl rAMPK.26 Incubations were performed in 25 ju.L

|

Materials and Methods

of AMPKK assay buffer (20 mmol/L Tris, 5 mmol/L MgCL,

Male Sprague-Dawley rats (250 to 350 grams; Charles River

0.2 mmol/L ATP, 0.5 mmol/L DTT, 0.1% Tween, 1 mg/mL bovine

Laboratories, Inc, Wilmington, Mass) were given standard chow and

serum albumin; pH 7.5). In experiments designed to assess the

water before experiments. All procedures were approved by the Yale

effects of nucleotides on AMPKK activity, AMP (0 to 200 p.mol/L),

University Animal Care and Use Committee.

ATP (400 /rmol/L tolO mmol/L), and ZMP (0 to 1000 /umol/L,
Sigma, St. Louis, Mo) were added to the incubation

Rats were anesthetized with pentobarbital sodium (60 mg/kg intiaperitoneal) and heparinized (300 U intraperitoneal). Hearts were
excised and anterogradely perfused in the working mode with
Krebs-Henseleit buffer containing

mixture.

Samples were diluted with Laemmli buffer, subjected to SDS-PAGE,

In Vitro Low-Flow Ischemia

1%

bovine

serum

albumin.

0.4 mmol/L oleate, and 5 mmol/L glucose, and equilibrated with
95% CK/5% C02 at 37°C.25 Control hearts were perfused at a preload
of 15 cm H20 and an afterload of 100 cm H20 for 40 minutes.
Ischemic hearts were perfused normally for 20 minutes and then flow
was reduced to 15% of control (by decreasing afterload pressure to
30 cm ILO) for I to 20 minutes. Hearts were freeze-clamped in

and immunoblotted with anti-pThr172 AMPK and pan-a AMPK
antibodies.

AMPK Activity Assay
Endogenous heart AMPK activity, as well as the catalytic activity of
rAMPK incubated with AMPKK, were assessed with a kinase assay
measuring the incorporation of [y-12P|-ATP into the SAMS pep¬
tide.13 Endogenous AMPK activity was measured using 10 p.g of
2.5% to 6% PEG fraction protein prepared from heart homogenates.
The activity of a,1'312 fusion protein or heterotrimeric rAMPK used
as AMPKK substrates was measured after isolation with a Ni-NTA

liquid nitrogen and stored at — SO^C.

kit (Qiagen, Valencia, Calif),

which bound the epitope-tagged

recombinant proteins via their polyhistidine sequences.

In Vivo Regional Ischemia
Anesthetized rats were endotracheally intubated and ventilated with
a small animal respirator, and drey underwent thoracotomy to ligate
the proximal left coronary artery for 10 minutes. Control rats

Statistics
Results were analyzed using Student t lest and are presented as
means±SEM. Results were significant at P<0.05.

underwent sham thoracotomy. Hearts were then rapidly excised and
freeze-clamped in liquid nitrogen.

Results

In Vivo AICAR Infusion

AMPK and AMPKK Fractions

The AMPK-activator 5-amino-4-imidazolecarboxamide (AICAR)

We initially evaluated whether AMPK and AMPKK might be

(Sigma, St. Louis, Mo), which is converted to the monophosphory-

separately enriched using PEG precipitation of heart homog¬

lated metabolite ZMP that is an AMP mimetic, was administered

enates. Immunoblots demonstrated that endogenous AMPK

intravenously (100 mg/kg bolus and 10 mg/kg per minute infusion
for 60

minutes)

to chronically

catheterized rats.1 Control

rats

was present predominantly in the 2.5% to 6% PEG fraction

received saline infusions. Plasma glucose was maintained constant

(Figure 1A), whereas AMPKK activity was almost exclu¬

with a variable infusion of 20% dextrose to prevent hypoglycemia, as

sively in the 6% to 10% fraction (Figure IB). Conditions for

previously described.1 At the end of the infusion, rats were anesthe¬

optimizing the AMPKK assay

tized with intravenous pentobarbital (50 mg/kg), and tire hearts were

AMPKK activity was found to be linear for 20 minutes

rapidly excised and freeze-clamped in liquid nitrogen.

(Figure

Heart tissue was homogenized in buffer containing 125 mmol/L Tris.
mmol/L EDTA,

1

mmol/L

then

1C), using up to 25 jug of 6% to

established.
10% PEG-

precipitated protein from ischemic hearts (Figure ID), so that

Tissue Fractionation
1

were

EGTA,

50 mmol/L NaF, 5 mmol/L NaPPi,

250

mmol/L

mannitol,

AMPKK assays were subsequently performed with 10 /ug
protein for 10 minutes.

1 mmol/L DTT, 1 mmol/L

7.5).13 After centrifugation at I4 000g for 20 minutes, the superna¬

AMPK and AMPKK Activity During In
Vitro Ischemia

tant was fractionated by the sequential addition of polyethylenegly¬

We next assessed whether ischemia activated AMPK and

benzamedine. 0.004% trypsin inhibitor, and 3 mmol/L NaN, (pH

col (PEG) into 2.5% to 6% and 6% to 10% precipitants and >10%
supernatant. Fractions were resuspended in homogenizaiton buffer
without mannitol. Protein concentrations were determined using the

AMPKK activity in perfused working rat hearts. Endogenous
AMPK Thr172 phosphorylation (Figure 2A) and activity (Fig¬

Bradford assay (BioRad reagent).

ure 2B) increased 2- to 3-fold (P<0.01) after low-flow

Immunoblotting

meric a,/3,yl rAMPK as substrate demonstrated a 4- to 5-fold

ischemia. Incubation of the AMPKK fraction with heterotri¬
Proteins were diluted in Laemmli

sample buffer before SDS-

PAGE.13 After transfer to polyvinylidine difluoride membranes,
proteins were immunoblotted with pan-a (a,/a2) AMPK antibody at
1:10 000 dilution (kind gift from Dr M. Bimbaum) and anti-pThr172
AMPK antibody at 1:5000 dilution (Cell Signaling, Beverly, Mass).

(P<0.01) increase in AMPKK activity in ischemic hearts
(Figure 2C). The increase in ischemic heart AMPKK activity
was very rapid, increasing 3-fold after 1 minute and reaching
maximal activity by 5 to 20 minutes. The accumulation of

Proteins were detected with enhanced chemiluminescence and auto¬

phosphorylated AMPK was less rapid (P<0.05), but also

radiographs were quantified using densitometry.

significant, during the first 2 minutes of ischemia, and was
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Effects of AMP on Heart AMPKK Activity
In Vitro

maximal after 5 to 20 minutes. Because AMPK was not
present in the AMPKK fraction, there was no detectable
endogenous phosphorylated Thr1,2 AMPK in the incubations.

To determine whether heart AMPKK is activated directly by
AMP, perfused heart AMPKK was incubated with varying
concentrations of AMP and either the a,1 312 fusion protein or
a,)3iyl rAMPK containing an R70Q mutation in the y, AMP
binding site. These substrates enabled assessment of the
direct effects of AMP on AMPKK, without the potentially
confounding effect of AMP interacting with the heterotrimeric complex to render the substrates more effective targets
for AMPKK. With the addition of physiologic concentrations
of AMP (10 to 200 /amol/L) found in the ischemic heart,20-27
there was no augmentation of AMPKK-stimulated Thr1 2
phosphorylation (Figure 4A and 4B) or the catalytic activities
(Figure 4C and 4D) of these rAMPK substrates.

Effects of In Vivo Ischemia on AMPK and
AMPKK Activity
To determine whether AMPKK was also activated by regional
ischemia in the intact rat in vivo, we measured AMPK and
AMPKK activity after coronary occlusion. Regional ischemia
stimulated endogenous AMPK phosphorylation (Figure 3A) and
increased AMPK activity 3-fold (P<0.01) (Figure 3B). Re¬
gional ischemia also stimulated AMPKK activity: phosphoryla¬
tion ofa,|3,yl rAMPK increased significantly (P<0.05) (Figure
| 3D), and the phosphorylation of the a/'312 also tended to be
| greater after in vivo ischemia (Figure 3C).
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Figure 1. Enrichment of AMPK and
AMPK kinase (AMPKK) activity in heart
homogenate fractions. A, Ischemic heart
homogenates were fractionated using
PEG precipitation and immunoblotted
with pan-a AMPK antibody (*P<0.01 vs
both 6% to 10% and >10%). B, PEG
fractions (25 pig protein) were incubated
with 10 pmol a,1'312 fusion protein for 10
minutes, a-,1'312 was then immunoblotted
with pThr'72 and pan-a AMPK antibodies
to measure AMPKK activity (*P<0.01 vs
both 2.5% to 6% and >10% fractions).
C, AMPKK (10 pig protein from 6% to
10% fraction) from ischemic hearts was
incubated with 5 pmol a,j6,y1 rAMPK
(*P<0.01 vs 0 minutes). D, AMPKK was
incubated with 5 pmol a,^yl rAMPK for
10 minutes. rAMPK was then immuno¬
blotted with pThr172 and pan-a AMPK
antibodies to measure AMPKK activity
(*P<0.01 vs 5 pig AMPKK). Values are
means±SE for 3 independent
experiments.

S* 3

it.

Perfusion 1_20
time (min) Control

Figure 2. Kinetics of AMPK and AMPKK
activation in the in vitro ischemic heart
AMPK and AMPKK activities were assessed
in the working heart model after control or
low-flow ischemic perfusions. A Endoge¬
nous heart AMPK was immunoblotted with
pThr172 and pan-a AMPK antibodies. B, En¬
dogenous AMPK activity was measured in
the 2.5% to 6% PEG fraction of heart ho¬
mogenates using the SAMS peptide as a
substrate (*P<0.01 vs 1-minute control;
tP<0.01 vs 20-minute control). C, a,/3iy1
rAMPK (5 pmol) was incubated with heart
AMPKK (10 jug) for 10 minutes and then
immunoblotted with pThr172 and pan-a
AMPK antibodies to measure AMPKK activ¬
ity (*P<0.05 vs 1-minute control; fPcO.OI vs
20-minute control). Values are meansiSE
for 3 independent experiments.
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Figure 3. AMPK and AMPKK activation in
the in vivo ischemic heart. Heart AMPK and
AMPKK activity after sham operation (n=7)
or regional ischemia (n=6) for 10 minutes in
vivo. A, Endogenous heart AMPK was immunoblotted with pThr172 and pan-a AMPK
antibodies. B, AMPK activity was measured
in 2.5% to 6% PEG fractions using the
SAMS peptide assay (*P<0.01 vs control). C
and D, AMPKK (10 /ug) activity was
assessed with a,1'312 fusion protein (10
pmol) or
rAMPK (5 pmol) substrates
that were immunoblotted with pThr172 and
pan-o AMPK antibodies. The relative
amount of phosphorylated substrate is
quantified in the bar graphs (§P<0.15,
tP<0.05 vs control). Values are meansiSE.

Ischemia

In contrast, the addition of AMP did enhance the action of

Effects of ATP on Heart AMPKK Action

heart AMPKK to phosphorylate (Figure 5A and 5B) and

ATP concentrations also decrease during ischemia:12-27 there¬

increase the catalytic activity (Figure 5C and 5D) of rAMPKs

fore. we examined the hypothesis that normal physiologic

containing intact AMP-binding domains (a,/3,yl or a:/3,yl).

concentrations of ATP might inhibit AMPKK directly or

AMP clearly

augmented the ability of ischemic heart

inhibit the ability of AMPK to be phosphorylated by heart

AMPKK to activate the a,j3,yl and a2j3,yl rAMPKs (Figure

AMPKK. Heart AMPKK was incubated with varying ATP

5). Although AMP had little discernible effect to increase

concentrations and either the truncated a,1'312 fusion protein

rAMPK Thr172 phosphorylation (Figure 5Aand 5B), it did

or heterotrimeric a1/3,yl rAMPK (Figure 7). ATP (5 to

slightly and significantly increase the ability of control heart

10 mmol/L) had no effect on AMPKK-mediated phosphory¬

AMPKK to stimulate rAMPK activity (Figure 5C and 5D).

lation of the a,1'312 fusion protein (Figure 7A) but did

Taken together, these observations suggest that AMP inter¬

significantly inhibit the ability of AMPKK to phosphorylate

action with rAMPKs containing functional y subunits renders

ai/3,yl rAMPK (Figure 7B). These results indicate that

the a subunits better substrates for Thr12 phosphorylation,

physiologic intracellular concentrations of ATP indirectly

particularly by ischemic heart AMPKK.

inhibit the action of heart AMPKK through interaction with
the heterotrimeric AMPK complex.

Effects of AICAR Infusion and ZMP on Heart
AMPKK Activity

Discussion

To further examine the physiological importance of nucleo¬

These results elucidate the dual mechanisms regulating the

tide interaction with the y subunit in mediating AMPK

phosphorylation and activation of AMPK by upstream AMP-

phosphorylation by heart AMPKK, we assessed the mecha¬

KK(s) in the ischemic heart. First, AMPKK activity per se is

nisms by which AICAR activates AMPK in the heart.3

increased by both low-flow ischemia in vitro and regional

AICAR is converted to the AMP mimetic compound ZMP28

ischemia in vivo. Second, AMP and ATP interactions with

and is known to activate heart AMPK activity in vivo.3

the heterotrimeric AMPK complex reciprocally modulate its

AICAR infusion increased heart AMPK Thr1 2 phosphoryla¬

suitability as a substrate to be phosphorylated by heart

tion (Figure 6A) but had no effect on heart AMPKK activity,

AMPKK. The findings suggest that the increases in AMP and

as assessed in vitro with either the a,1-312 fusion protein or the

decreases in ATP concentrations that occur in the ischemic

a,j3,yl rAMPK (Figure 6B and 6C). Interestingly, ZMP had

heart12-20-27 have an indirect influence on AMPKK action,

no effect to stimulate AMPKK phosphorylation of the trun¬

rather than a direct effect on AMPKK activity. In addition,

cated a,1'312 fusion protein (Figure 6B), but it clearly in¬

the results of the AICAR/ZMP experiments further demon¬

creased the ability of heterotrimeric a,/3,yl rAMPK to be

strate that the interaction of nucleotides with heterotrimeric

phosphorylated by AMPKK (Figure 6C). These results sug¬

AMPK are important and sufficient to increase AMPK Thr172

gest that the AMP mimetic ZMP potentiates AMPKK action

phosphorylation in vivo, even in the absence of direct heart

through interaction with the y subunit, rendering AMPK a

AMPKK activation.

better substrate for the upstream kinase. In the absence of

Both in vitro and in vivo myocardial ischemia caused

AMPKK activation, this physiological mechanism appears to

significant increases in AMPKK activity in these experi¬

account for AICAR-stimulated AMPK phosphorylation in the

ments. In contrast, previous studies in noncardiac tissues and

heart in vivo.

cells have observed greater AMPK phosphorylation and
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Figure 4. Effect of AMP on heart AMPKK phosphorylation of rAMPK substrates lacking AMP-binding capacity. Heart AMPKK activity
after control or low-flow ischemic perfusions was measured as the phosphorylation of a,1-312 fusion protein (A) or a,/3,-yl rAMPK con¬
taining an R70Q mutation in the yi AMP-binding site (B) in the absence or presence of AMP (10 to 200 pmol/L). After incubations with
AMPKK, substrates were immunoblotted with pThr172 and pan n-AMPK antibodies and their relative phosphorylation was quantified in
the bar graphs. The activities of the isolated a!1’312 fusion protein (C) and R70Q mutated a-ifay 1 rAMPK (D) were then measured using
the SAMS peptide as a substrate. The AMP concentration in panels C and D refers to that present during incubations with AMPKK.
Values are means±SE for 3 independent experiments (*P<0.01 vs control group).
activation in the absence of increased AMPKK activity.

AMPKK activity has not been assessed in these experi¬

Hypoglycemia increased Thr172 phosphorylation and AMPK

ments and the specific mediators of presumed AMPKK

activity without altering AMPKK activity in INS-1 cells.24

activation in these settings remain unknown.

Similarly, in situ contraction increased AMPK phosphoryla¬

In contrast, when AMP was added to ischemic heart

tion in skeletal muscle without increasing the activity of

AMPKK incubated with intact heterotrimeric a./Tyl

LKB1,29 a recently identified AMPKK.23 30 Although these

a2/3,yI rAMPK, we observed an increase in a subunit Thr172

Findings raised the possibility that AMPKK might be consti-

phosphorylation and AMPK activity. These results, taken

tutively active, this does not appear to be the case in the heart

together with the a, fusion protein and R70Q a,jB, yl rAMPK

during ischemic stress.

findings, are consistent with the hypothesis that AMP-binding

The mechanisms by which AMPKK action is increased

or

to the y subunit induces a conformational change in the

in the ischemic heart were elucidated through the use of

heterotrimeric AMPK complex, which renders the a subunit

different substrates to measure AMPKK activity. Both the

more susceptible to phosphorylation by AMPKK.223132 In¬

a,1'312 fusion protein24 and heterotrimeric rAMPKs26 were

terestingly, we found less striking effects of AMP to render

effective substrates for the heart AMPKK assay in vitro.

AMPK a better substrate for nonischemic heart AMPKK,

Measurement of AMPKK activity in the absence of AMP

raising the possibility that activated AMPKK from the ische¬

demonstrated intrinsic AMPKK activation in the ischemic

mic heart may better-recognize the change in AMPK confor¬

heart. The use of rAMPK substrates without normally

mation induced by AMP-binding to the y subunit. Although

functional AMP-binding sites (a,1'312 fusion protein and

these studies were not designed to assess protein phospha¬

OijSiyl rAMPK R70Q mutation) in the AMPKK assays

tases in the ischemic heart, it is possible that AMP binding to

also enabled us to demonstrate that AMP has no direct

the y subunit may also decrease the susceptibility of a

effects to increase AMPKK activity. AMPK activation in

subunit pThr172 to dephosphoryladon by heart protein phos¬

the absence of measurable changes in the AMP concentra¬

phatases, as previously shown in liver.19

tion has been implicated in the response of noncardiac

In the ischemic heart, inhibition of oxidative metabolism

tissues to leptin,18 osmotic stress,16 and metformin,16-17 but

causes ATP breakdown and leads to the formation of AMP
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Figure 5. Effects of AMP on the action of heart AMPKK to phosphorylate intact heterotrimeric rAMPK. Heart AMPKK activity after con¬
trol or low-flow ischemic perfusions was measured as the phosphorylation of a,/3iy1 (A) or a2/3iy1 (B) rAMPK substrates in the absence
or presence of AMP (10 to 200 /xmol/L). After incubations with AMPKK, substrates were immunoblotted with pThr172 AMPK and pan
a-AMPK antibodies (upper panels) and their relative phosphorylation was quantified in the bar graphs (lower panels), a^/Tyl rAMPK (C)
or a2/3iy1 rAMPK (D) were isolated and their activities measured using the SAMS peptide as a substrate. The AMP concentration in
panels C and D refers to that present during incubations with AMPKK. Values are means±SE for 3 independent experiments (*P<0.01
vs control group, tP<0.05 vs 0 /rmol/L AMP).

through the action of adenylate kinase.33 Our results indicate

significantly different from those surrounding Thr,172 suggest¬

that the decline in ATP concentration, which occurs in the

ing that distinct upstream kinases are responsible for their

ischemic heart,12-27 may also contribute to the phosphoryla¬

phosphorylation.32 In addition, glycogen may modulate

tion and activation of AMPK. The concentrations of ATP (5

AMPK activity through interaction with the j8 subunit glyco¬

to 10 mmol/L) present in heart under nonischemic condi¬

gen binding domain.34 The (3 subunit also contains several

tions12-27 clearly inhibited AMPKK phosphorylation of

phosphorylation sites,10-32 including Ser108, which may be

rAMPK substrate that contained an intact y subunit AMP

autophosphorylated by the a subunit.32 Whereas this study

binding site. However, these same concentrations of ATP had

provides insight into the ischemic regulation of Thr172 phos¬

no discernible effect to inhibit AMPKK activity directly, as

phorylation by AMPKK, the physiologic regulation and role

assessed using the a,1'312 fusion protein as substrate. Thus,

of these additional AMPK phosphorylation sites in the heart

these findings suggest that AMP and ATP interact with the

remain to be determined.

AMPK complex in a reciprocal fashion to modulate its

AMPK is activated in the ischemic heart1 and increases

suitability as an AMPKK substrate, rather than acting directly

glucose transport by stimulating GLUT4 translocation to the

on AMPKK.

sarcolemma3 and activates phosphofructokinase-2, which ac¬

This study focused on AMPKK phosphorylation of the

celerates glycolysis.4 Recent results indicate that transgenic

critical a subunit Thrl7:-activating site. The a subunits

mice, expressing a dominant-negative AMPK catalytic sub¬

contain additional phosphorylation sites, Thr258 and Ser485

unit. have impaired ischemic12 and postischemic glucose

(a,)/Ser491 (a,), but they do not appear to be important

uptake.12-35 AMPK-deficient hearts demonstrate poor recov¬

determinants of AMPK catalytic activity.32 The amino acid

ery of left ventricular function, increased necrosis, and

sequences surrounding the Thr258 and Ser483 residues are

myocyte apoptosis after low-flow ischemia and reperfusion,12
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suggesting that AMPK may have a cardioprotective role in

vation may be attributable to dissociation of LKB1 from

the heart during ischemia-reperfusion. These results highlight

STRAD and/or M025, two modifier proteins that form a

the importance of further understanding the upstream path¬

functional complex with LKB1 and potentiate its Thr172

ways involved in AMPK activation in the ischemic heart.

phosphorylation activity.23 Further investigation is needed to

Recent studies have identified the tumor suppressor LKB 1

delineate the role of LKB1, STRAD a/(3, and M025 a/(3 in

to be an upstream AMPKK in the liver.23-30 Although we have

modulating AMPKK activity in the heart. However, liver

observed that the heart AMPKK fraction contains LKB1,

LKB 1 does not appear to be AMP-responsive,23 consistent

LKB 1 is also present in PEG fractions that have no detectable

with our findings that AMP did not directly increase heart

AMPKK activity (unpublished data, 2004). The latter obser¬

AMPKK activity.
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Although we found detectable baseline AMPKK activity

8. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman

and endogenous AMPK Thr172 phosphorylation in vivo and in

GI. AMP kinase is required for mitochondrial biogenesis in skeletal

vitro in the heart, AMPKK is clearly not fully activated in the

muscle in response to chronic energy deprivation. PNAS. 2002,99:
15983-15987.

nonischemic heart. The effects of anesthesia or the few

9. Stein SC, Woods A, Jones NA, Davison MD, Carling D, The regulation

seconds required to excise and freeze-clamp the hearts might

of AMP-activated protein kinase by phosphorylation. Biochem J. 2000;
345:437-443.

have contributed to the baseline AMPKK activity observed in

10. Warden SM, Richardson C, O’Donnell J, Jr., Stapleton D. Kemp BE,

vivo in sham-operated rats and to some extent led to under¬

Witters LA. Post-translational modifications of the heta-1 subunit of

estimation of the degree of activation of AMPKK during

AMP-activated protein kmase affect enzyme activity and cellular local¬
ization. Biochem J. 2001;354:275-283.

regional ischemia. These effects together with the inherent
variability of sampling in the regional model of ischemia may

11. Carling D, Fryer LG, Woods A, Daniel T, Jarvic SL, Whitrow H.
Bypassing the glucose/fatty acid cycle: AMP-activatcd protein kinase.

explain in part why the degree of activation of AMPKK in the
ischemic isolated perfused hearts was greater than in the in

Biochem Soc Trans. 2003;3 111 57-1 160.
12. Russell RR, 3rd, Li i, Coven DL, Pypaert M, Zechner C, Palmeri M,
Giordano FJ, Mu J, Birnbaum MJ. Young LH AMP-activated protein

vivo hearts.

kinase mediates ischemic glucose uptake and prevents postisehemic

Since the initial submission of this manuscript, Altarejos et
al have presented evidence that AMPKK is activated in the
ischemic heart without a measurable increase in AMP con¬

cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004; 1 14:
495-503.
13. Coven DL, Hu X, Cong L, Bergeron R. Shulman GI, Hardie DG, Young
LH. Physiological role of AMP-activated protein kinase in the heart:

centration or change in LKB1 activity.36 These observations
are consistent with and complement our results, further

graded activation during exercise. Am J Plivsiol Endocrinol Metab. 2003;
285:E629-E636.

supporting tire conclusion that AMPKK activation is AMP-

14. Salt I, Celler JW, Hawley SA. Prescott A, Woods A, Carling D, Hardie

independent in the ischemic heart and highlighting the need

DG. AMP-activated protein kinase: greater AMP dependence, and pref¬
erential nuclear localization, of complexes containing the alpha2 isoform.

to identify additional AMPKK(s) in the heart and the mech¬
anisms activating these upstream kinase(s).

Biochem J. 1998;334:177-187.
15. Hayashi T, Hirshman MF, Fujii N. Habinowski SA, Witters LA.
Goodyear LJ. Metabolic stress and altered glucose transport: activation of

In conclusion, this study demonstrates that there are dual

AMP-activated protein kinase as a unifying coupling mechanism.

mechanisms operative in the ischemic heart that regulate
AMPKK-mediated phosphorylation and activation of AMPK.

Diabetes. 2000;49:527-531.
16. Fryer LGD. Parbu-Patel A, Carling D. The anti-diabetic drugs rosigli-

Further understanding the molecular identity of AMPKK(s)

tazone and metformin stimulate AMP-aclivaled protein kinase through

in the heart will be important as AMPK emerges as a critical

distinct pathways. J Biol Chem. 2002;M202489200.
17. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre

signaling pathway in the ischemic heart.

J. Doebber T, Fujii N, Musi N, Hirshman MF. Goodyear LJ, Moller DE.
Role of AMP-activated protein kinase in mechanism of metformin action.
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